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Kurzzusammenfassung 
Zytokine sind kleine, sezernierte Proteine mit regulatorischen Funktionen in vielen 
biologischen Prozessen, einschließlich der Immunantwort. Eine Dysregulation der 
Zytokin-Signaltransduktion spielt oft eine maßgebliche Rolle bei der Entstehung und 
Aufrechterhaltung von akuten und chronischen Entzündungen. Aktuelle Anti-Zytokin-
Therapien haben wesentlich dazu beigetragen die Behandlung entzündlicher 
Erkrankungen zu verbessern. Medikamente gegen Zytokine gehören in der Regel zur 
Gruppe der Biologika, wie zum Beispiel neutralisierende Antikörper oder auch lösliche 
Rezeptoren. 
Zur Inhibition von Zytokinen, die über heteromere Rezeptorkomplexe signalisieren, 
entwickelten wir eine Strategie, welche auf der Fusion der Ligandenbindungsdomänen 
der beteiligten Rezeptoruntereinheiten basiert. Diese Rezeptor-Fusions-Proteine (RFP) 
sind höchst effektiv, hochspezifisch, monogen, und eignen sich daher besonders für 
gentherapeutische Ansätze. 
Der erste Teil dieser Arbeit befasst sich mit der Entwicklung eines neuartigen RFP gegen 
murines Interleukin-31 (IL-31). IL-31 wird hauptsächlich mit entzündlichen 
Hauterkrankungen in Verbindung gebracht, und signalisiert über einen heterodimeren 
Rezeptorkomplex bestehend aus dem Interleukin-31-Rezeptor (IL-31R) und dem 
Oncostatin M-Rezeptor (OSMR). Die Fusion der Domänen D1-D4 des murinen OSMR 
und der Domänen D1-D2 des murinen IL-31R verbunden durch einen flexiblen Linker 
führt zu einem effektiven Inhibitor von murinem IL-31 (mIL-31-RFP). Um das 
inhibitorische Potential des mIL-31-RFP zu untersuchen, entwickelten und 
charakterisierten wir ein Zell-basiertes System zur Analyse der murinen IL-31- und 
OSM-abhängigen Signaltransduktion. mIL-31-RFP inhibiert spezifisch die IL-31-
induzierte Signaltransduktion und hemmt nicht die Aktivität von murinem OSM. 
Im zweiten Teil dieser Arbeit, untersuchten wir, auch als Machbarkeitsnachweis für 
weitere monogene RFPs, die Verwendung des zuvor beschriebenen mIL-6-RFP zur 
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Inhibition von Interleukin-6 (IL-6) in vivo. Dazu wurden transgene Mäuse, die mIL-6-
RFP induzierbar und gewebespezifisch exprimieren, generiert und charakterisiert. 
In einem parallelen Ansatz, wurde mIL-6-RFP weiterentwickelt, um zum einen die 
inhibitorische Aktivität über die Fusion mit dem Fc-Anteil von murinem IgG2a (mIL-6-
RFP-Fc) zu erhöhen, und zum anderen über eine Codon-Optimierung der mIL-6-RFP-
Fc cDNA eine Steigerung der Protein-Expression zu erreichen. Nach direkter 
Applikation in Mäuse hemmte rekombinantes mIL-6-RFP-Fc die IL-6-induzierte 
Aktivierung des Transkriptionsfaktors STAT3 und der ERK1/2-Kinasen in der Leber 
und Niere. Gentransfer durch hydrodynamische Plasmid-Transfektion in Mäuse führte 
zur hepatischen mIL-6-RFP-Fc-Expression und Sekretion in das Blut in erheblichen 
Mengen. mIL-6-RFP-Fc inhibierte die hepatische Akut-Phase-Protein-Synthese und 
verbesserte die Nierenfunktion in einem renalen Ischämie und Reperfusions-
Krankheitsmodell.  
Die hier beschriebene Strategie ist auf viele weitere Zytokine, die zur Entwicklung von 
akuten und chronisch Entzündungen und anderen Krankheiten beitragen, übertragbar. 
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Abstract  
Cytokines are small soluble proteins with regulatory functions in many biological pro-
cesses including immune responses. Dysregulated cytokine signaling is often responsible 
for the development and maintenance of acute and chronic inflammation. Current anti-
cytokine therapies have substantially improved the treatment of inflammatory diseases. 
Cytokine-targeting drugs are usually biologics such as neutralizing antibodies or soluble 
receptors. To target cytokines that signal through heteromeric receptor complexes we 
developed a strategy that involves the inline fusion of the ligand binding domains of the 
corresponding receptor subunits. These receptor fusion proteins (RFPs) are highly po-
tent and specific, monogenic by design, and therefore well suited for gene transfer ap-
proaches. 
The first part of this project deals with the development of a novel RFP targeting murine 
interleukin-31 (IL-31). IL-31, mostly involved in skin diseases, signals through hetero-
dimeric receptor complexes comprised of the interleukin-31 receptor (IL-31R) and the 
oncostatin M receptor (OSMR) subunits. Inline fusion of domains D1-D4 of murine 
OSMR and domains D1-D2 of murine IL-31R connected by a flexible linker results in a 
potent inhibitor for murine IL-31 (mIL-31-RFP). To assess the inhibitory potential of 
mIL-31-RFP we established and characterized a cell-based system for the analysis of 
murine IL-31 and oncostatin M (OSM) signaling. mIL-31-RFP specifically inhibits IL-
31-dependent signal-transduction and does not interfere with the activity of mOSM.  
In the second part of this project, we investigated, as a proof-of-principle for other 
monogenic RFPs, the potential of the previously described mIL-6-RFP to inhibit inter-
leukin-6 (IL-6) in vivo. Therefore, transgenic mice that express mIL-6-RFP in an induc-
ible and tissue-specific manner were generated and characterized.  
In a parallel approach, we re-engineered mIL-6-RFP by fusion to the Fc of mIgG2a 
(mIL-6-RFP-Fc) for enhanced inhibitory activity and improved protein expression by 
codon optimization. Upon application in mice, recombinant mIL-6-RFP-Fc inhibited 
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IL-6-induced activation of the transcription factor STAT3 and ERK1/2 kinases in liver 
and kidney. Gene transfer through hydrodynamic plasmid delivery in mice resulted in 
hepatic production and secretion of mIL-6-RFP-Fc into the blood in considerable 
amounts, blocked hepatic acute-phase protein synthesis and improved kidney function 
in a renal ischemia and reperfusion injury model.  
The strategy described here is applicable for many cytokines involved in inflammatory 
and other diseases. 
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1 Introduction 
1.1 Cytokines 
Cytokines are small soluble proteins with regulatory functions in many biological pro-
cesses including immune responses. In contrast to hormones, cytokines are generally 
produced de novo and secreted by different cell types in response to certain stimuli. Re-
leased cytokines act in autocrine or paracrine fashion and modulate pro- or anti-
inflammatory responses. Cytokines are further classified according to their biological 
functions into the groups of interferons, interleukins, colony stimulating factors and 
chemokines. 
1.2 Class I cytokine receptors 
The family of class I cytokine receptors, also termed hematopoietic receptors were clas-
sified through common structural features (Bazan, 1990, Wells and de Vos, 1996). Their 
extracellular part contains a common cytokine-binding module (CBM), which is built 
up by two fibronectin type-III like (FnIII-like) domains with distinctive motifs. The N-
terminal domain contains a set of four conserved cysteines, whereas the C-terminal 
(membrane-proximal) domain contains a collection of spaced aromatic residues termed 
WSXWS box. In contrast to receptor-tyrosine-kinases, class I cytokine receptors have 
no intrinsic kinase activity within their cytoplasmic parts and are instead associated with 
tyrosine-kinases of the Janus kinase (Jak)-family.  
1.3 Interleukin-6 family of cytokines 
The family of IL-6 type cytokines (Figure 1) consists of interleukin-6 (IL-6), interleukin-
11 (IL-11), leukemia inhibitory factor (LIF), cardiotrophin-1 (CT-1), ciliary neu-
rotrophic factor (CNTF), neuropoetin (NP), cardiotrophin-like cytokine (CLC), on-
costatin M (OSM), interleukin-31 (IL-31), interleukin-27 (IL-27) and interleukin-35 
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(IL-35). Structurally IL-6 type cytokines belong to the family of four-helix bundle cyto-
kines (Bazan, 1990). The composite cytokines IL-27 and IL-35 are heterodimeric cyto-
kines and also members of the IL-12 family of cytokines, where they represent the nega-
tive immunoregulatory members (Vignali and Kuchroo, 2012). IL-27 (Pflanz et al., 
2002) and IL-35 (Collison et al., 2012) are composed of the α-chain p28 or p35, respec-
tively, and the β-chain Epstein-Barr virus induced gene 3 (EBI-3). Both α-chains share 
the four-helix bundle structure characteristic of the IL-6 type cytokines, whereas EBI-3 
shares homology with class I cytokine receptors.  With IL-31 being the exception, all IL-
6 type cytokines share glycoprotein 130 (gp130) as a common receptor subunit. IL-31 
signals instead through the interleukin-31 receptor (IL-31R) subunit, which shows high 
homology to gp130 as evident by its alternative name gp130 like protein (GPL). 
 
Figure 1: IL-6 type cytokines IL-6 type cytokines signal via the formation of homo- or heter-
omeric receptor complexes. IL-6 and IL-11 signal after binding to their corresponding α-
receptors through gp130 homodimers, whereas LIF, CT-1, CNTF, NP and the composite cyto-
kine CLC/cytokine like factor-1 (CLF-1) signal through LIF receptor (LIFR)/gp130 heterodimer-
ic complexes. Both OSM and IL-31 signal through the OSM receptor (OSMR) in conjunction 
with gp130 or IL-31R, respectively. The composite cytokines IL-27 signal through IL-27 recep-
tor (IL-27R)/gp130 complexes, whereas IL-35 signal through IL-12 receptor β2 (IL-
12R2)/gp130 complexes.  
1.4 Interleukin-6 
Before consenting on a common nomenclature (Coulie et al., 1987b), IL-6 had several 
other synonyms, like interferon (IFN) β2 (Weissenbach et al., 1980), hepatocyte-
stimulating factor (Ritchie and Fuller, 1983), interleukin-HP1 (Van Snick et al., 1987) 
and 26-kDA-protein (Content et al., 1985) during its discovery phase by independent 
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studies, but its cDNA was originally cloned and characterized as B-cell stimulatory fac-
tor-2 (BSF-2) that drives the growth and differentiation of B-cells to immunoglobulin-
producing cells (Hirano et al., 1986).  
As evident by the different names given IL-6 exerts pleiotropic effects on several cell 
types (Figure 2). It can act as a growth factor on plasmacytoma (Nordan and Potter, 
1986) or myeloma cells (Kawano et al., 1988), suppresses differentiation of osteoclast 
progenitors (Yoshitake et al., 2008) and induces IL-2 production, proliferation and dif-
ferentiation of T cells (Garman et al., 1987, Lotz et al., 1988, Okada et al., 1988). Another 
T cell specific function is the ability of IL-6, in combination with transforming growth 
factor-β (TGF-β), to regulate the differentiation of naive cluster of differentiation 4+ 
(CD4+) T helper (Th) cells into Th17 cells, which produce the inflammatory cytokine 
IL-17 (Kimura and Kishimoto, 2010). Besides controlling proliferation and differentia-
tion of different cell types, IL-6 plays a major role in the regulation of the acute phase 
protein synthesis of the liver (Gauldie et al., 1987, Andus et al., 1987). Another im-
portant role of IL-6 is the regulation of metabolic functions (Mauer et al., 2015). IL-6-/- 
mice develop mature-onset obesity (Wallenius et al., 2002). In rats IL-6  treatment leads 
to an increased liver catabolism of glycogen and decreased mRNA expression of phos-
phoenolpyruvate carboxykinase (PEPCK), a key enzyme in gluconeogenesis, leading to 
the depletion of glycogen stores in the liver (Lienenluke and Christ, 2007). In mice, adi-
pocyte-derived IL-6 directly acts on hepatocytes, leading to the decreased expression of 
glucose-6-phosphatase (Reilly et al., 2015). Glucose-6-phosphatase catalyzes the termi-
nal step of glycogenolysis and gluconeogenesis and therefore plays a key role in the ho-
meostatic regulation of blood glucose levels. 
Main sources for IL-6 are fibroblasts, endothelial cells, monocytes and macrophages 
(Kishimoto et al., 1995). Other cell types such as astrocytes, smooth muscle cells, 
keratinocytes, mesangial cells, T cells and B cells synthesize IL-6 after stimulation with 
various factors (Tanaka et al., 2014). IL-6 synthesis and secretion is induced through 
responses to viral infections, other cytokines, such as IL-1, tumor necrosis factor-α 
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(TNF) and toll-like receptor (TLR)-mediated signals like lipopolysaccharides (LPS) 
(Coulie et al., 1987a, Tanaka et al., 2014).  
The amino acid sequence of human IL-6 consists of 212 amino acids with a signal pep-
tide of 27 amino acids. The secreted protein has a molecular mass of 26 kDa. Mouse IL-
6 shows 40% sequence homology on the protein level (Simpson et al., 1988). The serum 
levels of IL-6 for healthy human subjects range from 5-20 pg/ml (Kleiner et al., 2013). 
 
Figure 2: Pleiotropic effects of IL-6 Schematic representation of IL-6 controlled effects on a 
selection of cell types. Adapted from (Tanaka et al., 2012). 
1.4.1 The IL-6 receptors 
The signaling complex of IL-6 is composed of the signal-transducing β-receptor subunit 
gp130 (Taga et al., 1989) and the non-signaling IL-6 receptor α (IL-6Rα) (Yamasaki et 
al., 1988). The extra-cellular part of gp130 consists of a single immunoglobulin (Ig)-like 
domain (D1) followed by five FnIII-like domains (D2-D6) (Hibi et al., 1990). IL-6Rα 
consists of an Ig-like domain (D1), followed by a cytokine binding module (CBM) com-
prised of two FnIII-like domains (D2+D3) connected through a flexible stalk-region to 
its trans-membrane-domain. While gp130 is ubiquitously expressed (Saito et al., 1992), 
IL-6Rα expression is restricted to certain cell types like hepatocytes, intestinal epithelial 
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cells (Shirota et al., 1990), megakaryocytes and subsets of leukocytes and myeloid cells. 
IL-6 binding to its receptors is mediated by three receptor binding epitopes termed sites 
I, II and III. Receptor engagement starts with the formation of an IL-6/IL-6Rα complex 
through a low affinity interaction (KD=1 nM) (Taga et al., 1989) between site I of IL-6 
with the CBM (D2+D3) of IL-6Rα. Subsequently the IL-6/IL-6Rα complex binds to 
gp130 with a high affinity interaction (KD=10 pM). Through its site II, IL-6 binds the 
CBM (D2+D3) of one gp130 and with its site III the Ig-like domain (D1) of another 
gp130 molecule. The same is true for a second IL-6 molecule leading to the formation of 
a highly symmetric hexameric IL-6/IL-6Rα/gp130 complex in a 2:2:2 stoichiometry sta-
bilized by six cytokine–receptor interactions (Boulanger et al., 2003). Cells that lack IL-
6Rα are not responsive to IL-6, but can be triggered to induce IL-6-dependent signal 
transduction by stimulation with the agonistic soluble IL-6Rα (sIL-6Rα) in complex 
with IL-6. The stimulation of cells with IL-6/sIL-6Rα is termed trans-signaling (Rose-
John and Heinrich, 1994), while classical signaling refers to signaling through the mem-
brane bound IL-6Rα. Generation of the soluble receptor occurs either by shedding 
(Mullberg et al., 1993) or alternative splicing (Müller-Newen et al., 1996). Serum con-
centrations of the agonistic sIL-6Rα range around 50 ng/ml (Müller-Newen et al., 1996). 
Soluble gp130 (sgp130) is found at a serum concentration of about 300 ng/ml, and has 
been found to act antagonistically on IL-6/sIL-6Rα complexes (Narazaki et al., 1993, 
Müller-Newen et al., 1998). Low concentrations of sgp130 specifically inhibit IL-6 trans-
signaling, but sgp130 can also lead to inhibition of classical signaling depending on the 
ratio of IL-6 and sIL-6Rα (Jostock et al., 2001, Garbers et al., 2011, Müller-Newen et al., 
1998).  
1 Introduction 25 
 
Figure 3: IL-6 receptors and their structures Schematic representation of the domain 
structures of IL-6 receptor subunits and formation of the hexameric IL-6 receptor complex 
after binding of IL-6. 
1.4.2 IL-6 signal transduction 
Upon assembly of the hexameric signaling complex, IL-6 induces the activation of the 
Janus kinase (Jak)/Signal Transducer and Activator of Transcription (STAT) signaling 
pathway (Heinrich et al., 2003), the mitogen activated protein kinase (MAPK) cascade, 
as well as the phosphoinositide 3-kinase (PI3K) cascade (Eulenfeld et al., 2012). While 
gp130 mediates intracellular signal transduction through Jak-activation, the cytoplasmic 
part of IL-6Rα has no known signal-transducing function (Taga et al., 1989). Jak1, Jak2 
and Tyrosine kinase 2 (Tyk2) are the intrinsic kinases associated with gp130 through 
box 1 and box 2 binding motifs within the membrane-proximal cytoplasmic tail 
(Lupardus et al., 2011). Jak1 plays a crucial role after IL-6 dependent activation 
(Guschin et al., 1995). After complex assembly, Jaks are brought into close proximity to 
each other, allowing their auto-phosphorylation and subsequent phosphorylation of the 
tyrosine motifs within the cytoplasmic parts of gp130. The phosphotyrosine motifs then 
serve as binding sites for Src-homology 2 (SH2) domain containing proteins, including 
STAT transcription factors. After IL-6 dependent activation of gp130, mainly STAT3 
and to a lesser extent STAT1, are recruited to the receptor. After binding STATs become 
tyrosine-phosphorylated, dissociate from the receptor and dimerize through intermo-
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lecular phosphotyrosine/SH2-domain interactions. Phosphorylated and dimerized 
STAT factors then translocate to the nucleus where they bind enhancer elements on the 
DNA to promote induction of target genes. 
 
Figure 4: IL-6 dependent Jak/STAT signaling Binding of IL-6 to either membrane-bound or 
soluble IL-6Rα leads to the formation of the hexameric signaling complex, autophosphoryla-
tion of gp-130 associated JAKs and subsequent phosphorylation of tyrosine residues located 
on the cytoplasmic portion of gp130. STAT proteins are recruited to the receptor, become 
activated through tyrosine phosphorylation, dimerize and translocate to the nucleus where 
they induce target gene expression. 
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1.4.3 IL-6 and its role in inflammation 
In the innate immune response IL-6 plays a major role by the induction of acute phase 
protein synthesis in hepatocytes, following IL-6-dependent activation of STAT3 
(Wegenka et al., 1994). In the adaptive immune response IL-6 leads to the differentia-
tion from B cells to antibody-producing plasma cells (Hirano et al., 1986) and together 
with TGF-β drives the differentiation of naïve T cells to Th17 cells (Bettelli et al., 2006). 
IL-6 plays a major role in maintaining the balance between regulatory T cells (Treg) and 
Th17 cells (Kimura and Kishimoto, 2010), by favoring Th17 cell induction while inhib-
iting Treg cell development. IL-6 is further able to modulate T cell differentiation of 
CD4+ T cells in an autocrine manner towards Th2 differentiation by inducing IL-4 ex-
pression (Sofi et al., 2009). 
1.4.4 Pathophysiology of IL-6 
Dysregulated IL-6 expression has been implicated in the development of several diseas-
es. The involvement of IL-6 and its contribution to the pathogenesis of disease was first 
discovered in cases of primary tumors of the heart, called cardiac myxoma. Increased 
IL-6 levels were found in myxoma culture fluid and derived tissues from patients 
(Hirano et al., 1987), and are responsible for the observed constitutional symptoms and 
immunologic abnormalities (Mendoza et al., 2001). Increased IL-6 production was also 
found in synovial cells of rheumatoid arthritis (RA) patients (Hirano et al., 1988), swol-
len lymph nodes of patients with Castleman’s disease (Yoshizaki et al., 1989), and mul-
tiple myeloma cells (Kawano et al., 1988).  
Inflammatory Bowel Diseases 
IL-6 has further been shown to contribute to the development and inflammatory bowel 
diseases including both sporadic and colitis-associated colorectal cancer (Waldner et al., 
2012). In colitis-associated cancer IL-6 is a critical tumor promoter during early tumor-
igenesis, by enhancing proliferation of tumor-initiating cells (Grivennikov et al., 2009).  
1 Introduction 28 
Renal diseases 
A role for IL-6 has also been implicated in the development of renal diseases (Jones et 
al., 2015). Pro-inflammatory effects have been observed in murine lupus nephritis 
(Kiberd, 1993). However, in the nephrotoxic nephritis (NTN) model of acute crescentic 
glomerulonephritis (GN) protective effects by IL-6 have been observed. There IL-6 leads 
to the down-regulation of pro-inflammatory macrophage proliferation (Luig et al., 
2015).  
Autoimmunity 
IL-6 is further linked to the development of autoimmunity-related diseases through its 
major contributions to Th17 cell development. IL-6-/- mice are resistant to the induction 
of experimental autoimmune encephalomyelitis (EAE), partly because they expand Treg 
cells rather than Th17 cells (Korn et al., 2007). IL-6 upregulates the receptors for IL-23 
and IL-21 in naïve T cells, both of which are at a later stage important for Th17 cell phe-
notype development (Ivanov et al., 2006, Zhou et al., 2007).  
1.5 Interleukin-31 
IL-31 was first discovered in conditioned media of activated CD4+ T helper cells (Dillon 
et al., 2004). IL-31 shares the four-helix bundle architecture of the IL-6 family of cyto-
kines and belongs structurally to the subgroup of short-chain (Sc) cytokines (Sprang 
and Fernando Bazan, 1993). The human IL-31 gene has been mapped to chromosome 
12 whereas the mouse homologue is located on chromosome 5. Besides activated T-
cells, other cells have been implicated as sources for IL-31. Human mast cells were 
shown to produce and release IL-31 after stimulation with antimicrobial peptides 
(Niyonsaba et al., 2010), transcriptionally regulated by nuclear factor of activated T cells 
(NFAT) and STAT6 (Park et al., 2012). Human eosinophils were shown to express and 
secrete high levels of IL-31 after stimulation with staphylococcus enterotoxin B (SEB) 
(Kunsleben et al., 2015). Monocytes, macrophages, immature and mature monocyte-
derived dendritic cells produce IL-31 in response to ultraviolet (UV) irradiation and 
1 Introduction 29 
hydrogen peroxide (H2O2) treatment (Cornelissen et al., 2011). The serum levels of IL-
31 for healthy human subjects range from 6-10 ng/ml (Kim et al., 2011). 
1.5.1 Interleukin-31 receptors 
 
Figure 5: IL-31 receptors and their structure Schematic representation of the domain 
structures of IL-31 receptor subunits and formation of the trimeric IL-31 receptor complex 
after binding of IL-31. 
IL-31 is the only cytokine of the IL-6 family that does not signal through gp130 but 
through a most closely related receptor originally termed gp130-like monocyte receptor 
(GLM-R) (Ghilardi et al., 2002) or gp130-like receptor (GPL) (Diveu et al., 2003) and is 
now referred to as IL-31R (Figure 5). It shares the typical architecture and structural 
features of type I cytokine receptors, and is found in close physical proximity to gp130 
on human chromosome 5 and mouse chromosome 13. In contrast to gp130, IL-31R 
does not contain an N-terminal Ig-like domain. Therefore, IL-31R cannot bind to site 
III of IL-31 but instead binds with its CBM (D1+D2) to site II of the cytokine. Stimula-
tion with IFN-γ leads to upregulation of IL-31R expression on monocytes (Ghilardi et 
al., 2002) and dendritic cells in a STAT1 dependent manner (Horejs-Hoeck et al., 2012). 
In murine macrophages IL-31R expression is regulated by IL-4-induced STAT6 activa-
tion (Edukulla et al., 2015). The OSMR is the second receptor component in the IL-31 
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receptor complex and binds with its Ig-like domain D2 to site III of IL-31 (Le Saux et al., 
2010). Both receptor subunits are constitutively expressed on cells in the skin, testis, 
thymus and neurons of adult dorsal root ganglia (Dillon et al., 2004, Bando et al., 2006). 
1.5.2 IL-31 signaling 
Upon assembly of the heterotrimeric signaling complex, IL-31 induces the activation of 
the Jak/STAT signaling pathway (Heinrich et al., 2003) the MAPK cascade, as well as the 
PI3K cascade. Jak1 and Jak2 are the kinases associated with the OSMR/IL-31R signaling 
complex. After complex assembly, Jaks are brought into close proximity to each other, 
allowing their auto-phosphorylation and subsequent phosphorylation of the tyrosine 
motifs within the cytoplasmic parts of OSMR and IL-31R. The tyrosine motifs at posi-
tion Y652 and Y721 on IL-31R serve as STAT3 and STAT5 binding sites (Ghilardi et al., 
2002). Unlike OSMR, IL-31R is unable to recruit the adapter proteins SH2 domain con-
taining protein tyrosine phosphatase-2 (SHP-2) or SH2 domain containing transform-
ing protein (Shc), and thereby fails to mediate the phosphorylation of extracellular sig-
nal-regulated kinases (ERK)1/2  (Dreuw et al., 2004). Activation of the MAPK cascade is 
thereby mediated by the OSMR subunit and recruitment of Shc (Hermanns et al., 2000). 
1.5.3  Pathophysiology of IL-31 
In transgenic mouse models, the overexpression of IL-31 led to severe pruritus, alopecia 
and skin lesions (Dillon et al., 2004). In NC/Nga mice, an animal model of atopic der-
matitis (Takaoka et al., 2005), expression of IL-31 mRNA was increased. Treatment with 
an antibody targeting the IL-31R in the same model reduced the characteristic scratch-
ing behavior, but did not influence the development of dermatitis (Grimstad et al., 
2009). A recent study showed that repeated administration of IL-31 to BALB/C or 
NC/Nga mice leads to gradually upregulated IL-31R mRNA and protein expression in 
cutaneous dorsal root ganglia and correlates with increased long lasting scratching be-
havior (Arai et al., 2015). 
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IL-31 expression is increased in patients with atopic dermatitis (AD) but also in those 
with allergic contact dermatitis (ACD), arguing for an involvement in pruritic skin dis-
eases (Bilsborough et al., 2006, Neis et al., 2006, Sonkoly et al., 2006). IL-31R mRNA 
expression is upregulated in diseased tissue from animal models of airway hyper respon-
siveness (Dillon et al., 2004). Sera of patients diagnosed with allergic asthma show in-
creased levels of IL-31 (Neis et al., 2006). These findings indicate that IL-31 may con-
tribute to the development of Th2-related diseases.  
IL-31R-/- mice show a significant reduction in the number of immature hematopoietic 
progenitor cells (Broxmeyer et al., 2007). Parasitic infection of IL-31R-/- mice results in 
excessive Th2 inflammation, and therefore IL-31 may also mediate anti-inflammatory 
signals (Perrigoue et al., 2007, Perrigoue et al., 2009). Loss of IL-31R might lead to in-
creased OSM signaling capacity as the shared receptor subunit is no longer occupied in 
the IL-31 signaling complexes and therefore alters the OSM/IL-31 signaling balance 
towards OSM (Bilsborough et al., 2010), resulting in a shift of the target gene expression 
profile. 
1.6 Anti-cytokine therapies 
Dysregulated cytokine signaling is of central importance in many diseases such as 
chronic inflammation and cancer. Therapeutic strategies aim to interfere with dysregu-
lated cytokine signaling by specific inhibition of signaling pathways at different levels. 
Besides targeting of cytokine-receptor-interactions by biologics, through i.e. neutraliz-
ing antibodies or fused soluble receptors, also small molecule inhibitors targeting the 
intracellular signaling cascade have often been proposed as potential treatments for in-
flammatory diseases driven by cytokines. As there is great redundancy in the main sig-
naling pathways already between members of the IL-6 family of cytokines, effects of 
small molecule inhibitors targeting i.e. kinases or transcription factors might lead to 
adverse side effects. Therefore it should be achieved to inhibit the pathological relevant 
signaling pathway already at the level of cytokine-receptor-interaction in a highly specif-
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ic way. Current biological treatments are characterized by highly specific interactions 
with their relevant immune target. 
1.6.1 Strategies targeting IL-6 
As potential therapeutics for the implicated diseases and to further clarify the contribu-
tion of IL-6 several biologicals have been developed (Figure 6). 
 
Figure 6: Anti-IL-6 therapies approved for the clinics or in clinical phases An overview 
about anti-IL-6 therapies that globally block IL-6 and which are approved for clinical use. 
Although sgp130-Fc is still in clinical phase II for the treatment of inflammatory bowel dis-
eases, it is shown because it selectively blocks IL-6 trans-signaling. 
Tocilizumab (anti-IL-6Rα antibody) 
The first biological developed to target the IL-6Rα subunit is Tocilizumab, a humanized 
anti-IL-6Rα monoclonal IgG1 antibody. For its generation the complementarity deter-
mining regions of a mouse-anti-human IL-6Rα antibody were grafted onto human IgG1 
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(Sato et al., 1993). Tocilizumab blocks IL-6-mediated signal transduction by binding to 
either membrane-bound or soluble IL-6Rα making the receptors inaccessible for IL-6. 
The antibody is approved for the treatment of rheumatoid arthritis (Tanaka et al., 2013), 
systemic arthritis, juvenile idiopathic arthritis (Yokota et al., 2012) and Castleman’s dis-
ease (Nishimoto et al., 2005) in several countries. Various results of case and pilot stud-
ies indicate that Tocilizumab may be used for the treatment of various other chronic 
immune-mediated diseases governed by IL-6 (Kang et al., 2015). Tocilizumab further 
led to a significant reduction of apolipoprotein(a) serum levels in RA patients, and could 
therefore be an alternative to conventional lipid apheresis as a therapeutic approach to 
treat elevated lipoprotein(a) serum levels, thereby reducing the risk to the development 
of cardiovascular disease (Schultz et al., 2010, Mueller et al., 2015). 
Siltuximab (anti-IL-6 antibody)  
Another biological developed is Siltuximab, a chimeric human-murine IgG1κ antibody 
targeting human IL-6 (van Rhee et al., 2010). Siltuximab has been approved for the 
treatment of multicentric Castleman’s disease (Liu et al., 2014). Both Tocilizumab and 
Siltuximab block IL-6 signaling in a global manner, meaning inhibition of classical as 
well as trans-signaling.  
Sgp130-Fc 
A different approach is taken by another biological named sgp130-Fc. Sgp130-Fc is a 
fusion protein comprised of the extracellular part of gp130 (domains D1-D6) fused to 
the constant part (Fc) of a human IgG1 antibody. Fc-mediated dimerization of sgp130 
lead to a 10-fold higher inhibition of IL-6/sIL-6Rα induced trans-signaling than the nat-
ural sgp130 monomer (Jostock et al., 2001). With the help of sgp130-Fc it is possible 
distinguish if IL-6 contributes to the pathogenesis of diseases either via classical signal-
ing or trans-signaling. Inhibition of IL-6 trans-signaling has been shown to be beneficial 
in animal models of Crohn’s disease (CD), a chronic inflammatory disease of the gastro-
intestinal tract (Atreya et al., 2000). Sgp130-Fc is currently undergoing clinical phase II 
trials for the treatment of CD and ulcerative colitis. Besides implications of IL-6 trans-
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signaling in inflammatory bowel diseases (IBD), trans-signaling also seems to play a role 
in rheumatoid arthritis. Inhibition of IL-6 trans-signaling by sgp130-Fc effectively ame-
liorated disease hallmarks in an experimental mouse model of antigen-induced arthritis 
(AIA) (Nowell et al., 2003). 
Fused soluble receptors  
Another strategy to create an IL-6 inhibitor is based on the fusion of the extracellular 
parts of both gp130 and IL-6Rα with the constant part of a human IgG. Coexpression of 
both modified cDNAs in the expression host leads to Fc-mediated formation of disul-
fide-linked dimers (Economides et al., 2003). The limitation of this approach was the 
randomness of Fc-driven dimerization resulting in the expression of three distinct Fc-
dimer populations, namely sgp130-Fc, sIL-6Rα:sgp130-Fc and sIL-6Rα-Fc.  
In a parallel approach our lab developed a receptor fusion proteins targeting human IL-
6 (hIL-6-RFP) based on the inline-fusion of the ligand binding domains of gp130 and 
IL-6Rα, inhibiting IL-6 classical and trans-signaling in a highly specific manner. hIL-6-
RFP consists of domain D1-D3 of human gp130 fused to domains D2-D3 of human IL-
6Rα and targets specifically human IL-6 (Ancey et al., 2003). Following the same design 
principle but based on the murine receptor subunits a murine IL-6 receptor fusion pro-
tein (mIL-6-RFP) was developed, including domains D1-D3 of murine IL-6Rα (instead 
of just D2-D3) and D1-D3 of murine gp130. mIL-6-RFP binds murine, rat as well as 
human IL-6 (Wiesinger et al., 2009, Metz et al., 2007). In contrast to neutralizing anti-
bodies, RFPs are monogenic by design and therefore best suited for gene delivery ap-
proaches. They are useful tools to characterize cytokine contribution in murine models 
of human disease and could act as potential therapeutics in inflammatory diseases 
(Schwache and Müller-Newen, 2012). 
1.6.2 Strategies targeting IL-31 
As a potential therapeutic for pruritic skin diseases and to further clarify the contribu-
tion of IL-31 to pathogenesis, several biologicals targeting IL-31 have been developed. 
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Anti-IL-31 antibody 
The first biological developed is a monoclonal antibody directly targeting IL-31, which 
is developed by ZymoGenetics (acquired by Brystol-Meyer-Squib) and currently goes 
through clinical phase I for the treatment of atopic dermatitis (ClinicalTrials.gov Identi-
fier: NCT01614756). 
Anti-IL-31R antibody 
Another biological which targets IL-31 signal transduction is an anti-IL-31 receptor 
antibody, which has been shown to inhibit scratching behavior of IL-31 treated mice 
and to improve dermatitis scoring in a model of picryl-chloride induced contact hyper-
sensitivity, which resembles AD (Kasutani et al., 2014). 
OSMR-L-GPL 
Following the design principle of hIL-6-RFP (Ancey et al., 2003), a receptor fusion pro-
tein for the inhibition of human IL-31 has been generated called OSMR-L-GPL consist-
ing of D1–D4 of hOSMR connected with a flexible linker to D1–D2 of hIL-31R 
(Venereau et al., 2010). OSMR-L-GPL is a potent inhibitor of human IL-31 and does not 
inhibit human OSM signaling. In comparison to the previously described sOSMR and 
sIL-31R (sGPL) (Diveu et al., 2006), the inhibition of IL-31-dependent STAT3 phos-
phorylation by OSMR-L-GPL is more effective (Venereau et al., 2010).  
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2 Aim of the study 
To further clarify the role and contribution of IL-31 to inflammatory and allergic diseas-
es we wanted to develop a novel RFP based on the design of our previously described 
mOSM-RFP targeting murine interleukin-31. In addition an accompanying IL-31 re-
sponsive MEF cell system had to be developed for reliable analysis of IL-31 inhibitory 
studies. 
As a proof-of-principle for other monogenic RFPs, we wanted to investigate the poten-
tial use of mIL-6-RFP in transgenic mouse models as an in vivo research tool. Therefore 
transgenic mice that express mIL-6-RFP in a doxycycline-inducible and tissue specific 
promoter driven manner were to be generated and characterized. 
In a second approach we wanted to further optimize mIL-6-RFP to increase in vitro pro-
tein expression and facilitate protein purification. Additional improvements should lead 
to increased serum half-life in vivo. Therefore an engineered mIgG2a Fc-fragment fol-
lowed by a transferable tag for detection and quantification should be added to the C-
terminus to create mIL-6-RFP-Fc. To increase protein expression, mIL-6-RFP cDNA 
was optimized for mammalian codon usage. With the optimized mIL-6-RFP-Fc cDNA 
stably transfected producer cells were to be generated. The murine IgG2a Fc-fragment 
then should allow the purification of mIL-6-RFP-Fc through Protein A/G affinity chro-
matography for subsequent use of purified protein for in vitro and in vivo inhibition of 
IL-6.  
As RFPs are encoded by a single gene, they are well suited for gene therapeutic ap-
proaches. As a proof-of-principle for the applicability of RFPs to gene therapy, the op-
timized mIL-6-RFP-Fc gene should delivered to mice by means of hydrodynamics-
based transfection with subsequent analysis of pharmacodynamics of mIL-6-RFP-Fc 
and its therapeutic use in a model of ischemia/reperfusion in the kidney. 
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3 Materials and Methods 
Materials and methods are described according to standard protocols used in the Insti-
tute of Biochemistry and Molecular Biology, RWTH Aachen University, and were 
modified regarding individual differences in experimental procedures. 
3.1 Materials 
3.1.1 Chemicals 
All chemicals met at least the criteria for the purity standard pro analysi and were pur-
chased from Merck, Sigma-Aldrich, Roth or Invivogen.  
3.1.2 Buffers and Media 
All buffers and media were prepared with double-distilled water (ddH2O) unless stated 
otherwise. 
PBS 137 mM 
2.5 mM 
8 mM 
1.5 mM 
  
NaCl 
KCl 
Na2HPO4 
KH2PO4 
adjusted to pH 7.4 
RIPA lysis buffer 50 mM 
150 mM 
1 mM 
0.5 % 
1 mM 
15 % 
1 mM 
0.25 mM 
Tris-HCl, pH 7.4 
NaCl 
EDTA 
Nonidet P-40 
NaF 
glycerol 
Na3VO4  
phenylmethylsulfonylfluoride (PMSF) 
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5 μg/ml 
2.5 μg/ml 
aprotinin 
leupeptin 
TBS-N buffer 20 mM 
135 mM 
0.1 % 
Tris-HCl, pH 7.5 
NaCl 
Nonidet P-40 
3.1.3 Cytokines and soluble receptors 
Recombinant murine IL-6 and murine IL-31 were purchased from ImmunoTools (Frie-
soythe, Germany). Recombinant murine OSM was purchased from PeproTech (Rocky 
Hill, NJ). 
3.1.4 Oligonucleotides 
All oligonucleotides were ordered from Eurofins Genomics (Cologne, Germany). 
Table 1: List of sequencing primers 
Name Sequence 5‘ -> 3‘ 
BGH_as 
(#1.15) 
AACTAGAAGGCACAGTCG 
AGS41_as 
(DS26) 
CTTCCACCTCCACTACCAGC 
MCS-Koz_s 
(DS34) 
CGGTACTTAAGACAGGTACCGCCACC 
PPT_s 
(DS35) 
GATCCTAGCTCTTGTTGGAG 
gp130-I_as 
(LB14) 
TGAGGAGACCTTCCCAAGGG 
gp130-I_s 
(LB16) 
GAAGGTCTCCTCAGAGTCTATC 
IL-6R_as 
(LB17) 
GTTCTTCCGGAAGCAGGAGAGCTTG 
Table 2: List of cloning primers 
Name Sequence 5‘-3‘ 
mIL-31R_as GGCCAAGCTTTCAGGTACCTGGAACTTCCTCCATAGTCAC 
mIL-31R_s GTCCGCTAGCAGCCTGGCAGTCCTGCCGAC 
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3.1.5 Recombinant plasmids 
Name Description 
pOG44 Expression vector (Invitrogen, Paisley, UK); CMV pro-
moter; synthetic intron; FLP gene; ampicillin resistance 
(AmpR); pUC origin (ori)  
pUHrT 62-1 Expression vector (Urlinger et al., 2000); CMV promot-
er; AmpR; ori; encodes for rtTA2S-M2 
pCMV-Sport6 Expression vector (Invitrogen, Paisley, UK); T7, SP6, 
and CMV promoters; lox P site; AmpR; f1 ori 
pcDNA3 Expression vector (Invitrogen, Paisley, UK); CMV pro-
moter; T7 promoter; multiple cloning site (MCS); BGH 
polyadenylation signal (BGH-pA); f1 ori; SV40 promot-
er; neomycin resistance (NeoR); Sv40-pA; β-Lactamase 
promoter (bla); AmpR; pUC ori 
pcDNA5/FRT/TO Expression vector (Invitrogen, Paisley, UK); tetracycline 
controlled CMV promoter; T7 promoter; MCS; BGH-
pA; Flp-In recombination target (FRT); Hygromycin 
resistance (HygroR) without ATG; Sv40-pA; pUC ori; 
bla; AmpR; (After successful recombination into Flp-In 
sites hygromycin acquires the ATG required for expres-
sion.) 
pcDNA5/FRT/TO-spezial The vector pcDNA5/FRT/TO with a modified MCS 
pMA Transfer vector (Invitrogen, Paisley, UK) 
pTZ-PEPCK Expression vector 
IL-31/mIL-31-RFP 
Name Insert 
pCMV-Sport6 mIL-31R Isoform 4  
pcDNA3 mIL-31-RFP-3V5-3HA 
pcDNA5/FRT/TO mIL-31-RFP-3V5-3HA-his 
pcDNA5/FRT/TO mIL-31R Isoform 1 
IL-6/mIL-6-RFP 
Name Insert 
pcDNA3 mIL-6-RFP-V5-his  
pcDNA3 mIL-6-RFP-3V5-3HA 
pMA mIL-6-RFP-Fc-3V5-3HA (codon optimized cDNA) 
pcDNA3 mIL-6-RFP-Fc-3V5-3HA (codon optimized cDNA) 
pcDNA5/FRT/TO mIL-6-RFP-Fc-3V5-3HA (codon optimized cDNA) 
PTZ-PEPCK mIL-6-RFP-Fc-3V5-3HA (codon optimized cDNA) 
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3.1.6 Antibodies 
Anti-pY705-STAT3 (#9131), anti-STAT3 (#9139), anti-pERK1/2 (#4370), anti-ERK1/2 
(#9102) from Cell Signaling (Danvers, MA), anti-V5 (#R960-25) from Invitrogen 
(Carlsbad, CA), anti-STAT3 C-20, anti-STAT3 K-15 (#sc-482, #sc-483), anti-ERK1 (#sc-
093-G), anti-ERK2 (#sc-154-G), anti-GAPDH (#sc-32233) from Santa Cruz (Dallas, 
TX), anti-HSP70 (#ADI-SPA-820) from Enzo Life Sciences (Lörrach, Germany), and 
anti-HA (#H6908) from Sigma-Aldrich (St. Louis, MO) were used for immunoblotting. 
Anti-rabbit, anti-mouse and anti-goat antibodies conjugated to horseradish peroxidase 
were ordered from DAKO (Hamburg, Germany). 
3.2 Prokaryotic cells 
3.2.1 Bacterial strains 
E.-coli-bacterial strains were used for transformation and amplification of plasmid DNA 
DH5α F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG 
Φ80dlacZΔM15 Δ(lacZYA-argF)U169, hsdR17(rK- mK+), λ– 
JM83 rpsL ara Δ(lac-proAB) Φ80dlacZΔM15 
XL-1 blue endA1 gyrA96(nalR) thi-1 recA1 relA1 lac glnV44 F'[ ::Tn10 
proAB+ lacIq Δ(lacZ)M15] hsdR17(rK- mK+) 
JM110 rpsL thr leu thi lacY galK galT ara tonA tsx dam dcm glnV44 
Δ(lac-proAB) e14- [F' traD36 proAB+ lacIq lacZΔM15] 
hsdR17(rK-mK+) 
3.2.2 Media and cultivation 
Bacteria were either cultured in LB-medium, supplemented with a selection marker 
such as ampicillin or kanamycin (100 μg/ml) and incubated rocking with 250 rpm, or on 
LB-agar (1.5%) at 37°C. Storage of bacteria followed at -80°C in LB-Medium supple-
mented with 20% Glycerol (87%).  
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LB-Medium 10 g/l 
5 g/l 
5 g/l 
Bacto-Tryptone (Difco, Detroit, MI) 
Yeast extract (Difco, Detroit, MI) 
NaCl 
LB-Agar 15 g/l Bacto-Agar (in LB-Medium) (MP Biomedicals, 
Eschwege) 
3.2.3 Competent bacteria 
50 ml LB-medium were inoculated with a trace of the corresponding E. coli cells (XL-1 
blue, JM-83, JM-110, DH5α) from a glycerol stock vial and incubated at 37°C overnight 
to grow a preparatory culture, which is used the next day to inoculate 250 ml LB-
medium to start the bacterial culture. Shake the culture at 37°C until an OD600 of 0.6-0.8 
is reached (approximately 150 min). Cool the culture on ice for 5 min, and transfer the 
culture to a sterile, round-bottom centrifuge tube. Collect the cells by centrifugation (15 
min, 6000 rpm, 4°C). Discard the supernatant carefully and resuspend the pellet gently 
in 25 ml cold LB/PEG. 
LB-PEG 10 % 
5 % 
100 mM 
PEG (polyethylene glycol) 3350 or PEG 4000 
DMSO (dimethyl sulfoxide) 
MgCl2 
 Pass solution through a 0.2 μm sterile-filter and store at 4°C. 
Prepare aliquots of 200 μl in sterile microcentrifuge tubes and freeze in liquid nitrogen. 
Store the competent cells at –80°C. 
3.2.4 Transformation 
A 10 μl aliquot of the DNA to be transformed was transferred into a 1.5 ml microcentri-
fuge tube, and kept on ice. An aliquot of frozen competent E. coli cells was thawed on 
ice. The bacteria were gently resuspended cells and 50 μl of the cell suspension was 
transferred into the microcentrifuge tube with the plasmid DNA, mixed carefully, and 
kept on ice for 30 min. The tube was then transferred to a 42°C heating block for 90 sec-
onds and subsequently returned on ice for the next 2 min. The transformed bacteria 
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were then plated out on LB-agar plates containing the relevant antibiotic and incubated 
at 37°C overnight until colonies developed. 
3.3 Molecular biological methods 
3.3.1 Plasmid purification from bacterial cells 
Plasmid DNA from prokaryotic cultures was extracted using the QIAprep Spin Mini-
prep Kit (Qiagen) for small-scale preparations (5-15 μg) and the HiSpeed Plasmid Maxi 
Kits (Qiagen) for large-scale preparations according to the manufacturer’s recommen-
dations. Plasmid DNA was eluted using Merck H2O. 
3.3.2 Quantification of DNA 
Quantities of DNA were determined with NanoDrop 1000 spectrophotometer (Thermo 
Fisher Scientific, Waltham, MA) by photometric measurement of the absorption at 260 
nm (A260). An absorption-value of A260=1.0 is equal to an amount of 50 μg double 
stranded DNA. Purity of preparated nucleic acids was analyzed by measuring absorp-
tion at 280 nm (A280) additionally. For pure DNA the A260/A280 ratio should correspond 
to 1.8 – 2.0. 
3.3.3 Restriction endonuclease digestion of DNA 
Enzymatic restriction of DNA was performed according to manufacturer’s recommen-
dations. Restriction enzymes were purchased from New England Biolabs (Ipswich, MA). 
3.3.4 Agarose gel electrophoresis 
DNA fragments from either digested plasmid DNA or PCR products were mixed with 
DNA loading buffer and loaded onto a 1-1.5% agarose gel (SeaKem-LE-Agarose, Bi-
ozym, USA). The gel was run at 5 V/cm2 until the DNA fragments reached the required 
grade of separation. All agarose gels contained 0.5 μg/ml ethidium bromide for visuali-
zation of the DNA bands and were run in 1x TAE buffer. For size determination bands 
were compared with 1 Kb DNA ladder (Invitrogen, USA) marker. 
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10x DNA loading 
buffer 
0.25%  
0.25% 
30% 
Xylencyanol 
Bromphenol blue 
Ficoll 400 
1x TAE buffer 40 mM 
20 mM 
1 mM 
Tris-Base 
Acetic acid 
EDTA 
3.3.5 Isolation of DNA fragments from agarose gels 
The desired DNA fragments were cut out with a sterile scalpel and DNA was isolated 
using the QIAquick Gel Extraction Kit (Qiagen) following the manufacturer`s instruc-
tions. DNA was eluted in 30 μl chromatography grade water (Merck Millipore). 
3.3.6 Ligation of DNA 
The T4 DNA ligase (Roche, Mannheim, Germany) was used to ligate double stranded 
DNA fragments. 30 ng of linearized vector was incubated with a 3 fold molar excess of 
the insert for 60 min at room temperature. Then ligation preparations were transformed 
into competent bacteria. 
3.3.7 DNA Sequencing 
DNA was sequenced by Eurofins Genomics (Ebersberg, Germany). For sequencing 1 μg 
plasmid DNA was either premixed with 1.5 μl sequencing primer [10 pmol/μl] or stand-
ard primers supplied directly by Eurofins Genomics. 
3.3.8 Polymerase chain reaction (PCR) 
The PCR is used to selectively amplify a desired target DNA sequence. Standard PCR 
was performed according to the manufacturer’s recommendations using Taq Polymer-
ase. If the amplified DNA was to be used for further subcloning, the PCR was per-
formded using Phusion High Fidelity (HF) Polymerase (Finnzymes), which exhibits an 
intrinisic proof reading activity.  
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Taq Polymerase  
Master Mix 
for genotyping of 
transgenic mice 
4 μl 
5 μl  
2 μl 
2 μl 
1.5 μl 
1.5 μl 
1.5 μl 
0.3 μl 
ad 25 μl 
Tail DNA 
5x Taq-Polymerase Buffer 
DMSO 
MgCl2 
dNTPs 
Sense primer 
Anti-sense primer 
Taq Polymerase 
H2O 
Phusion HF 
polymerase 
x μl 
10 μl 
1 μl 
2.5 μl 
2.5 μl 
0.5 μl 
ad 50 μl 
DNA (5-10 ng) 
5x Phusion HF Buffer 
dNTPs 
Sense primer (10 pmol) 
Anti-sense primer (10 pmol) 
Phusion DNA Polymerase 
H2O 
 
3.3.9 RNA extraction 
Total RNA from cells or tissues was extracted with the RNeasy Mini Kit (Qiagen) ac-
cording to the manufacturer’s recommendations. The cell lysates were homogenized 
using the QIAShredder (Qiagen) columns. Remaining genomic DNA was digested on 
column using the RNase free DNase Set (Qiagen) for 15 min at room temperature. RNA 
concentration was determined using the Nanodrop 100 UV/VIS Spectrophotometer 
(Thermo Scientific). RNA was stored at -80°C. 
3.3.10 Reverse Transcription 
Complementary DNA (cDNA) was synthesized from 1 μg RNA using the OmniScript 
RT Kit (Qiagen) according to the manufacturer’s recommendations using either oligo-
dT or random hexamer primers.  
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3.4 Eukaryotic cells 
3.4.1 Cell lines 
HEK293 Adherent human embryonic kidney cells 
HepG2 Adherent human liver carcinoma cell line (ATCC HB-8065) 
MEF Adherent murine embryonic fibroblasts (Dr. B. Neel, Boston, 
USA) 
muHepa Murine hepatocarcinoma cells (kindly provided by Dr. Christian 
Liedtke, Department of Medicine III, RWTH Aachen Universi-
ty) 
Primary murine 
keratinocytes 
Kindly provided by Prof Dr. Jens Malte Baron, Department of 
Dermatology, RWTH Aachen University 
PAM212 Mouse keratinocyte cell line (kindly provided by Prof Dr. Jens 
Malte Baron, Department of Dermatology, RWTH Aachen Uni-
versity) 
3.4.2 Cultivation of eukaryotic cells 
HEK293, MEF, PAM212 and muHepa cells were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM, Lonza), supplemented with 10% fetal calf serum (FCS), 100 
mg/l streptomycin, and 60 mg/l penicillin. HepG2 cells were maintained in DMEM-F12 
medium (Lonza) supplemented with 10% FCS, 100 mg/l streptomycin, 60 mg/l penicil-
lin and 2 mM l-glutamine. The cells were incubated at 37°C in a water-saturated atmos-
phere at 5% CO2. All cells used were free of mycoplasma as determined by a PCR-based 
assay.  
3.4.3 Cryoconservation of eukaryotic cells 
Cells were grown to 80% confluency and either scraped or trypsinized. Cells were centri-
fuged, washed with PBS and resuspended in freezing medium. 1 ml aliquots were stored 
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3.4.4 Mammalian protein production and purification 
Stable HEK293 Flp-In/T-Rex cells (Invitrogen) for the inducible production of mIL-6-
RFP- Fc were generated with the Flp-In system using 250 μg/ml Hygromycin B (Invi-
vogen) and 15 μg/ml Blasticidin (Invivogen). Protein expression was induced in serum-
free medium with 400 ng/ml doxycycline (Sigma-Aldrich) for 72 hours. Harvested con-
ditioned media were cleared through centrifugation, passed through a 0.20 μm sterile-
filter and afterwards loaded onto an ÄKTA Purifier 10 system (GE Healthcare, Chalfont 
St. Giles, UK) for affinity purification on a 1 ml Protein A Sepharose Column (#89924, 
Thermo Fischer, Waltham, MA). The column was washed with 20 mM sodium phos-
phate buffer (pH 7). mIL-6-RFP-Fc was eluted in fractions of 1 ml using 12.5 mM citric 
acid (pH 2.7) and neutralized immediately by adding 50 μl of 2 M Tris/HCl (pH 8). Pro-
tein containing fractions were quantified using a BCA colorimetric assay (#500-0006, 
Bio-Rad, Munich, Germany) following manufacturer’s instruction. Protein containing 
fractions were pooled and dialyzed against PBS. 
3.4.5 Expression of mIL-6-RFP-Fc in vitro 
Murine hepatocarcinoma cells (kindly provided by Dr. Christian Liedtke, Department 
of Medicine III, RWTH Aachen University) were cultivated in Dulbecco’s Modified 
Eagle Medium (DMEM) with GlutaMax (Invitrogen) supplemented with 10% FCS 
(Lonza, Basel, Switzerland), 100 U/ml penicillin and 100 μg/ml streptomycin (Sigma-
Aldrich). For the cultivation of HepG2 cells (ATCC HB-8065) DMEM/F12 (Invitrogen) 
was used. The cells were incubated at 37°C in a water saturated atmosphere at 5% CO2 
and grown on 6-well plates to 70% confluence. All cells used in this study were free of 
mycoplasma as determined by a PCR-based assay. Cells were transfected using TransIT-
LT1 (Mirus Bio, Madison, WI) according to manufacturer’s instructions. Medium was 
exchanged to DMEM with GlutaMax™ without FCS after 4 hours. For analysis of protein 
secretion conditioned media were harvested at the indicated time points and cleared by 
centrifugation. 
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3.5 Cell biological and immunological methods 
3.5.1 Cell lysis 
For the isolation of cellular proteins, cell cultures were lysed in RIPA-lysis buffer (50 
mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% NP-40, 15% glycerol, 1 mM NaF, and 1 mM 
Na3VO4) supplemented with 5 μg/ml of each aprotinin, leupeptin and 0.25 mM PMSF as 
well as 0.5 mM EDTA.  
3.5.2 SDS-PAGE 
Protein containing samples were separated on a 7.5% or 10% polyacrylamid separating 
gel at 35 mA by discontinuous sodium dodecyl sulfate polyacrylamide gel electrophore-
sis (SDS-PAGE). 
3.5.3 Coomassie staining 
Following SDS-PAGE, proteins could be visualized in the gel with Coomassie Brilliant-
Blue G-250 (Diezel et al., 1972). The gels were first fixed in fixation solution (10% acetic 
acid, 25% isopropanol, H2O). After fixation, the gels were stained in coomassie staining 
solution (10% acetic acid, 30% isopropanol, 0.006% Coomassie Brilliant-Blue G-250, 
H2O) for 20 minutes at room temperature with constant agitation. The gels were then 
incubated in destaining solution (10% acetic acid, 40% methanol, H2O) until the back-
ground of the gel disappeared. 
3.5.4 Western blot and immuno-detection 
Proteins were separated by SDS-PAGE and transferred to a polyvinylidene-difluoride 
(PVDF) membrane (GE Healthcare). Membranes were washed in TBS-N and then 
blocked with 10% bovine serum albumin in TBS-N for 30 min. Membranes were ex-
posed to specific primary antibodies overnight at 4°C. Membranes were washed three 
times with TBS-N and subsequently incubated with horseradish-peroxidase (HRP)-
conjugated secondary antibodies for 1h at room temperature. Primary and HRP-
conjugated secondary antibodies were diluted in TBS-N buffer (20 mM Tris-HCl, pH 
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7.5, 135 mM NaCl, 0.1% Nonidet P-40). After washing the membrane three times sig-
nals membrane-bound antibody complexes were detected by chemiluminescence (pCA-
ECL solution (100 mM Tris-HCl pH 8.8, 2.5 mM luminol, 0.2 mM para coumaric acid, 
2.6 mM hydrogenperoxide). 
3.5.5 ELISA 
anti-mIL-6-Rα 
Concentrations of mIL-6-RFP were determined by a sandwich ELISA. A validated anti-
body combination directed against domains D1–D3 of the murine IL-6Rα was used 
(R&D Systems). Soluble mIL-6Rα (R&D Systems) served as a standard. 
anti-HA/anti-V5 
Microtiter plates (Nunc Maxisorp, Sigma) were coated overnight with anti-HA antibody 
(#MMS-101R, BioLegend, Dedham, MA) in sterile filtered PBS at 4°C. After blocking 
the plate for 1 hour with 1% BSA/PBS diluted standard and samples were added and 
incubated for 2 hours at room temperature. mIL-6-RFP-Fc bound to the plate was de-
tected by anti-V5-HRP (#R961-25, Invitrogen). The enzymatic reaction was performed 
with 3,3´,5,5´-tetramethylbenzidine (TMB) substrate, stopped in 2 M H2SO4 and the 
absorbance was measured at 450 nm on an EON Microplate Spectrophotometer (Bio-
Tek, Winooski, VT) and analyzed with Gen5 Software (BioTek). mIL-6-RFP quantified 
with the mIL-6Rα ELISA served as a standard. 
3.5.6 Inhibition of IL-6 in vitro 
muHepa cells were grown on 6 cm dishes to 70% confluence. A mixture of IL-6 (20 
ng/ml) and mIL-6-RFP-Fc (corresponding molar ratios) or PBS, respectively, was prein-
cubated in 1 ml DMEM for 30 min and afterwards added to the cells for 20 min. For 
pretreatment the medium was supplemented with 1335 ng/ml mIL-6-RFP-Fc (10-fold 
molar excess) 90’ prior stimulation with IL-6 (20 ng/ml). Subsequently, cells were 
washed with PBS once and lysed with RIPA lysis buffer. The proteins were separated by 
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SDS-PAGE and transferred to a PVDF membrane with subsequent immunodetection 
using specific antibodies. Primary and HRP-conjugated secondary antibodies were di-
luted in TBS-N buffer. The membrane was incubated with pCA-ECL solution (100 mM 
Tris-HCl pH 8.8, 2.5 mM luminol, 0.2 mM para coumaric acid, 2.6 mM hydrogenperox-
ide) and membrane-bound antibody complexes were detected by chemiluminescence 
using a digital imaging system (LAS 4000 mini, Fuji, Japan). 
The murine pre-B cell line Ba/F3 was stably transfected through electroporation with an 
expression vector encoding murine gp130. Ba/F3-mgp130 cell pools expressing mgp130 
in conjunction with the puromycin resistance gene were selected and maintained in the 
presence of 1.5 μg/ml puromycin (Invivogen) and IL-3. Ba/F3-mgp130 cells were retro-
virally transduced with mIL-6Rα using the pMOWS system as described elsewhere 48, 
selected and maintained in the presence of 1.5 μg/ml puromycin and 10 ng/ml IL-6. 
Ba/F3 cell lines were cultured in DMEM containing 10% FCS, 100 U/ml penicillin and 
100 U/ml streptomycin at 37°C with 5% CO2 in a water-saturated atmosphere. For the 
proliferation assay Ba/F3-mgp130-mIL6Rα were seeded on 96-well plates (20,000 
cells/well), and stimulated with IL-6 (37 pM) in the presence of either mIL-6-RFP-Fc- or 
mIL-6-RFP-conditioned media. After 60 h of incubation, metabolically active cells were 
quantified using a colorimetric assay based on the cell proliferation kit II XTT assay 
(Roche Diagnostics, Mannheim, Germany). 
3.6 Animal experiments 
All animal experiments have been approved by the local government authorities and 
were performed in accordance with relevant guidelines and regulations. Mice were held 
under a 12-hour light-dark cycle and had ad libitum access to drinking water and stand-
ard chow. Treatment groups were distributed equally among cages. For assessment of 
pharmacokinetics and for IL-6 injection experiments, matched male littermates aged 12-
20 weeks were used. Volumes of 100 and 200 μl were administered for i.v. and i.p. injec-
tions, respectively. Blood draws and euthanasia for organ harvesting were performed at 
the time points indicated. For subsequent quantitative protein analysis samples for 
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comparison were assayed on a single membrane or ELISA plate with equal amounts 
loaded and the experimenter having animal numbers rather than specified treatment 
group information. qPCR, serum creatinine measurements and tissue analysis were 
conducted in a completely blinded fashion. Serum creatinine was analyzed as described 
(Nagayama et al., 2014). 
3.6.1 Hydrodynamics-based in vivo gene delivery 
To obtain maximal expression levels, younger, i.e., 7 week-old male littermates were 
transfected via tail vein injection of plasmid PTZ-PEPCK-b.glob.intron-mIL-6-RFP-Fc-
3V5-3HA-b.glob.polyA prepared in delivery solution (TransIT-EE, Mirus Bio, Madison, 
WI). 
3.6.2 Renal ischemia and reperfusion procedure 
Seven-week-old male C57/Bl6J animals (purchased from Charles River, Sulzfeld, Ger-
many; allowed 1 week of acclimatization) hydrodynamically pre-transfected and exhib-
iting mIL-6-RFP-Fc levels of 0.25-4.5 μg/ml (as assessed by serum ELISA at 20 h post 
transfection) or having received 100% of the control plasmid volume i.v. were subjected 
to I/R. Mice were anaesthetized using Ketamin/Xylazin, acclimatized on a warmed elec-
trical plate for 15 min (constant plate temperature of 37°C), and subject to operation by 
midline laparotomy and subsequent clamping of both renal hila using mini clamps 
(#18055-04, Fine Science Tools, Heidelberg). Clamping was timed to be exactly 33 
minutes per each kidney while animals were held at a constant plate temperature of 
37°C. Completeness of ischemia of both kidney was assured by color changes of the en-
tire organ to a dark and lighter color during and following ischemia, respectively. Mice 
were sutured using standard techniques. Surgeons were blinded to the animals’ treat-
ment groups. Upon euthanasia at sacrifice animals were perfused intraarterially with 
saline 0.9 % prior to organ harvest. 
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3.6.3 Immunofluorescence 
Prior to liver harvesting by snap-freezing (TissueTek, Sakura, Japan) mice were perfused 
intra-arterially with saline 0.9 % upon euthanasia to minimize blood cell autofluores-
cence. Cryosections (5 μm) were fixed in 4 % paraformaldehyde for 15 min, blocked 
with 10 % donkey serum in PBS, and subsequently stained with rabbit anti-HA antibody 
(1:100), donkey anti-rabbit-cy3 (1:200, Dianova, Hamburg, Germany), and DAPI (4',6-
diamidino-2-phenylindole, 1:10000, Roche, Mannheim, Germany). GFP fluorescence 
was preserved during this procedure. A BZ-9000 microscope (Keyence, Japan) was used 
for visualization. 
3.6.4 Histology and renal tissue injury score 
Following harvest, right kidney halves were fixed in methyl Carnoy’s solution, embed-
ded in paraffin, sectioned (2 μm), and stained by periodic acid-Schiff (PAS) as described  
(Nagayama et al., 2014). Left kidney tissue was not available for PAS stain due to pro-
cessing for cryopreservation. Renal tissue injury was assessed in a blinded fashion by 
scoring the percentage of tubules in the outer medulla that exhibited tubular dilation / 
atrophy, cast formation, cellular necrosis and loss of brush border as follows: 0, none; 1, 
>0-25%; 2, 25 – 50%, 3, 50-75% and 4, > 75% as described (Howard et al., 2012). Six 
consecutive non-overlapping high-power fields (x 200) per section were examined. 
3.6.5 Preparation of liver and kidney lysates 
Tissue protein extracts were generated on ice using RIPA buffer and processed for 
Western blot analysis similar to cellular lysates (see above). Equal amounts of protein 
(30 μg) were loaded. 
3.6.6 Quantitative mRNA analysis 
Liver RNA isolation and cDNA synthesis were performed using standard columns (Qi-
agen, Hilden, Germany) and random primers (Roche), respectively. Real-time quantita-
tive PCR was carried out using qPCR Core Kit for SYBR Green (Eurogentec, Liege, Bel-
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gium) and an ABI Prism 7300 sequence detector (Life Technologies, Carlsbad, CA). 
Data were normalized using glyceraldehyde-3-phosphate dehydrogenase (Gapdh) as an 
internal control and calculated using the ΔΔCT-method. 
Table 3: List of qPCR primers 
Name Sequence 5‘-3‘ 
Gapdh_fwd GGC AAA TTC AAC GGC ACA GT 
Gapdh_rev AGA TGG TGA TGG GCT TCC C 
Saa1 QuantiTect Primer Assay, Mm_Saa1_1_SG, Catalog No. QT00196623, 
(Qiagen, Hilden, Germany) 
A2m_fwd TGC ATC CGG GTT GGT GTA C 
A2m_rev TTC ATA CAG ATG CAG TGA GAC TTT TG 
IL-6_fwd TGT TCA TAC AAT CAG AAT TGC CAT T 
IL-6_rev AGT CGG AGG CTT AAT TAC ACA TGT T 
Ngal_fwd GGC CTC AAG GAC GAC AAC A 
Ngal_rev TCA CCA CCC ATT CAG TTG TCA 
Saa1, serum amyloid A1; A2M, a-2macro-globulin; Ngal, Neutrophil gelatinase-
associated lipocalin (NGAL)/lipocalin-2 (Lcn2). 
3.6.7 Statistical analysis 
Unpaired one-sided student’s t-test with Welch’s correction when appropriate was per-
formed at all instances when not otherwise specified to compare control- and RFP-
treated groups as indicated using GraphPad Prism version 6.0b for Mac OS X, 
GraphPad Software (La Jolla, CA). The one-sided test approach was chosen since our 
hypothesis H1 was one-sided, i.e., mIL6-RFP-Fc inhibits IL-6 or is beneficial in the renal 
ischemia-reperfusion model compared to control. 
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4 Results 
4.1 Development of mIL-31-RFP 
The first part deals with the engineering and biochemical characterization of a receptor 
fusion protein targeting murine IL-31 (mIL-31-RFP). Through a combination of com-
putational analysis and site-directed mutagenesis the critical amino acids of human IL-
31 implicated in ligand receptor interaction with hOSM-R and hIL-31R were identified 
(Le Saux et al., 2010). As a site II/III cytokine IL-31 resembles OSM and LIF, which both 
signal through heterodimeric receptor complexes consisting of mgp130 (site II interac-
tion) and a cytokine specific receptor subunit mOSM-R and mLIF-R (site III interac-
tion), respectively. 
4.1.1 Cloning and expression of mIL-31-RFP 
The receptor signaling complex of IL-31 consists of OSMR and IL-31R. mIL-31-RFP is 
built up in analogy to the previously published receptor fusion protein for the inhibition 
of murine OSM (mOSM-RFP) (Brolund et al., 2011). mOSM-RFP consists of the four 
N-terminal domains of the murine OSM receptor (mOSMR) and domains D2 and D3 
of murine gp130 (mgp130) connected by a flexible polypeptide linker. To create mIL-
31-RFP the CBM of gp130 (D2 + D3) was replaced with the CBM of mIL-31R (Figure 
6A). The CBM of mIL-31R is highly homologous to gp130, and is formed by its domain 
D1 and D2 (see Supplementary Figure 1). Furthermore, the flag-tag at the C-terminus of 
mOSM-RFP was replaced with a 3V5-3HA tag module consisting of three consecutive 
V5 and HA tags which improves protein detection and facilitates quantification through 
a α-HA/α-V5 based sandwich-ELISA. The cDNA of isoform 4 of murine IL-31R (Uni-
prot: Q8K5B1-4) was obtained from imaGenes. The nucleotide sequence encoding D1 
and D2 of mIL-31R was amplified via PCR from pCMV-Sport6-mIL-31R and subse-
quently digested with NheI/HindIII. The digested PCR fragment was used to replace the 
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domains D2-D3 of mgp130 and the flag-tag in pcDNA3.1-mOSM-RFP-flag to create 
pcDNA3.1-mIL-31-RFP. In a second construct we introduced the 3V5-3HA tag, ampli-
fied from pcDNA3-Albumin via PCR and digested with KpnI/HindIII, to create 
pcDNA3.1-mIL-31-RFP-3V5-3HA. HEK293 cells were transfected with an expression 
vector encoding for mIL-31-RFP-3V5-3HA. Conditioned media of the cells were con-
centrated 10-fold, quantified and analyzed under either reducing or non-reducing con-
ditions by Western blotting using an antibody directed against the HA-tag (Figure 6B). 
The apparent molecular mass of reduced mIL-31-RFP is about 150 kDa, which is in 
agreement with the expected molecular mass of the glycosylated mIL-31-RFP. Under 
non-reducing conditions additional bands of higher molecular mass represent the for-
mation of mIL-31-RFP-3V5-3HA dimers and multimers. 
 
Figure 7: Design and expression of mIL-31-RFP (A) mIL-31-RFP was cloned on the basis of 
mOSM-RFP and consists of domain D1-D4 of murine OSMR connected through a flexible 
linker with D1-D2 of murine IL-31R followed by three V5 and three HA epitopes. Arrows indi-
cate binding of IL-31 to mIL-31-RFP. (B) Western blot analysis of reduced and non-reduced 
10-fold concentrated conditioned media from transiently transfected HEK293 cells, 
previously quantified with an α-V5/α-HA-based sandwich-ELISA for mIL-31-RFP-3V5-3HA. 
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4.1.2 Analysis of cell lines for IL-31 responsiveness 
To analyze the inhibitory function of mIL-31-RFP a model system to validate its biolog-
ical activity is needed. It is known, that undifferentiated normal human epidermal 
keratinocytes (NHEK) respond well to IFN-γ priming with increased IL-31R expression. 
Subsequent stimulation with IL-31 leads to phosphorylation of STAT3 (Heise et al., 
2009). Therefore we first analyzed the IL-31 signaling capabilities of primary murine 
keratinocytes and PAM 212 cells, a murine keratinocyte cell line (Figure 8). To possibly 
enhance or induce IL-31R expression, both cell lines were additionally primed with 20 
ng/ml IFN-γ for 24 hours prior to stimulation with IL-31. Stimulation with OSM served 
as a positive control for STAT3 phosphorylation. 
 
Figure 8: IL-31 responsiveness of primary murine keratinocytes and PAM212 cells 
Western blot analysis of IL-31 induced STAT3 phosphorylation on whole cell lysates of (A) 
primary murine keratinocytes stimulated with 50 ng/ml IL-31 for 10 to 60 minutes or 5 ng/ml 
OSM for 20 minutes, or (B) PAM212 cells stimulated with different concentrations of IL-31 or 
5 ng/ml OSM for 20 minutes.  
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Both, primary murine keratinocytes (Figure 8A) and PAM212 cells (Figure 8B), do not 
respond to IL-31 treatment with tyrosine phosphorylation of STAT3 (Figure 8A Lanes 
2-6, Figure 8B Lanes 2-5). Even after priming with 20 ng/ml IFN-γ for 24h no STAT3 
phosphorylation was detectable (Figure 8A Lanes 8-12, Figure 8B Lanes 7-10). In con-
trast, stimulation with OSM for 20 minutes resulted in STAT3 tyrosine phosphorylation 
(Figure 8A+B Lane 1), which was increased after IFN-γ priming (Figure 8A Lane 7, Fig-
ure 8B Lane 6).  
4.1.3 Engineering of an IL-31 responsive cell system 
To establish a reliable cellular system for subsequent analysis of IL-31 signaling and the 
inhibitory activity of mIL-31-RFP, mouse embryonic fibroblasts (MEF) cells, previously 
used to study the inhibitory function of mOSM-RFP and mLIF-RFP, were chosen. 
Wild-type (WT) MEF cells constitutively express the murine OSMR but lack mIL-31R 
and are therefore not capable of responding to IL-31 (Figure 9A). To obtain full-length 
mIL-31R the cDNA for isoform 4 of mIL-31R was amplified from pCMVSport6-mIL-
31R via PCR and cloned into pcDNA3.1. In a second step exons 13-16 of the mIL-31R 
gene were amplified via PCR from genomic DNA, fused to isoform 4 (Figure 9B) and 
cloned into the pcDNA5FRT/TO vector to obtain pcDNA5FRT/TO-mIL-31-R encod-
ing the full length receptor chain. This vector harbors a FLP recombination target (FRT) 
site which allows the Flp-recombinase-mediated integration of the vector into Flp-In 
host cell lines. Successful integration confers resistance to hygromycin B and allows se-
lection of positive cells. To generate a stable mIL-31R cell line, MEF Flp-In cells were 
co-transfected through electroporation with pcDNA5FRT/TO-mIL-31R and pOG44, 
encoding Flp-In recombinase. Transfected cells were selected by addition of 200 μg/ml 
hygromycin B and seeded at low density to select single cell clones. Whole cell lysates of 
well-growing clones were analyzed for mIL-31R expression via Western blotting using 
an antibody targeting the N-terminal part of mIL-31R. All selected clones showed 
mIL31-R expression (Figure 9C).  
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Figure 9: Rebuilding full-length mIL-31R cDNA from genomic DNA and generation of 
stably transfected MEF cells with IL-31 responsiveness (A) Western blot analysis of OSM- 
and IL-31 induced STAT3 phosphorylation on WT MEF cells. (B) Schematic view of the CDS of 
full-length mIL-31R and the corresponding exons needed to rebuild full-length mIL-31R. (C) 
Western blot analysis of whole cell lysates from stably transfected MEF mIL-31R clones. (D, E) 
Western blot analysis of (D) time- and (E) dose-dependent IL-31 induced STAT-3 phosphory-
lation on MEF mIL-31R clone 6. 
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For further experiments MEF mIL-31R clone 6 was selected. Time-dependent stimula-
tion of MEF mIL-31R clone 6 with 20 ng/ml mIL-31 lead to tyrosine phosphorylated 
STAT3 with maximal phosphorylation at 20 minutes (Figure 9D Lanes 3-6). OSM stim-
ulation served as a positive control (Figure 9D Lane 2). In comparison to OSM-induced 
STAT3 phosphorylation, where already low concentrations lead to strong STAT3 phos-
phorylation (Figure 9E Lanes 2-4), much higher concentrations of IL-31 are required to 
induce a similar degree of STAT3 phosphorylation (Figure 9E Lanes 5-10). 
4.1.4 mIL-31-RFP inhibits IL-31 induced STAT3 phosphorylation 
 
Figure 10: mIL-31-RFP inhibits IL-31 dependent STAT3 phosphorylation on MEF mIL-
31R cells MEF mIL-31R cells were stimulated with 15 ng/ml of IL-31 or 2.5 ng/ml OSM for 20 
min in the presence or absence of control or mIL-31-RFP conditioned media with corre-
sponding molar ratios towards IL-31. Whole cell lysates were separated by SDS/PAGE and 
analyzed via Western blotting. 
To test the IL-31 antagonizing activity of mIL-31-RFP, conditioned media of transiently 
transfected HEK293 cells were pre-incubated with IL-31 for 20 minutes to allow the 
cytokine to bind to the inhibitor. MEF mIL-31R cells were then stimulated for 20 
minutes with either IL-31 alone or IL-31/mIL-31-RFP at different molar ratios. To as-
sess the specificity of mIL-31-RFP cells were additionally stimulated with OSM and pre-
incubated OSM/mIL-31RFP. After 20 minutes cells were lysed and STAT3 phosphoryla-
tion was analyzed. Stimulation with IL-31 alone or pre-incubated with control condi-
tioned media from mock-transfected HEK293 cells lead to a prominent tyrosine phos-
phorylation of STAT3 (Figure 10 Lanes 4-5). Treatment of MEF cells with IL-31 pre-
incubated with increased volumes of conditioned media containing mIL-31-RFP result-
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ed in a reduction of tyrosine phosphorylation of STAT3 (Figure 10 Lanes 6-8). A 10-fold 
molar excess of mIL-31-RFP over IL-31 reduces STAT3 phosphorylation to nearly basal 
levels (Figure 10 Lane 8). mIL-31-RFP CM had no effect on OSM-induced STAT3-
phosphorylation (Figure 10 Lanes 11-12). Thus mIL-31-RFP effectively and specifically 
inhibits IL-31 signaling. 
4.1.5 Further modification of mIL-31-RFP 
As conditioned media contain a plethora of different proteins, that possibly affect other 
signaling pathways, it was desired to clone a mIL-31-RFP variant that can be easily puri-
fied and therefore be used in a defined formulation. We chose to add six histidine resi-
dues to the C-terminus, which allow the purification of mIL-31-RFP through immobi-
lized metal affinity chromatography (IMAC). Histidines bind to divalent metal ions like 
nickel around neutral pH, and can be eluted under specific buffer conditions. To clone 
this variant pcDNA5FRT/TO-mOSM-RFP-3V5-3HA-6his was digested with AgeI/KpnI 
to replace the gp130 CBM with the mIL-31R CBM from AgeI-/KpnI digested pcDNA3-
mIL-31-RFP-3V5-3HA to obtain pcDNA5FRT/TO-mIL-31-RFP-3V5-3HA-6his.  
4.1.6 Generation of mIL-31-RFP-3V5-3HA-his producing cell lines 
The pcDNA5FRT/TO mIL-31-RFP-3V5-3HA-6his vector allows the Flp-In site-
directed recombination of mIL-31-RFP-3V5-3HA-his into a Flp-In host cell line. Suc-
cessful integration after stable transfection confers resistance to hygromycin B and al-
lows selection of positive cells. To generate a stable mIL-31-RFP-3V5-3HA-his producer 
cell line HEK293 Flp-In/T-Rex cells were chosen. These cells contain a single stably in-
tegrated FRT site at a transcriptionally active genomic locus. In addition to the Flp-In 
site, these cells express the tet repressor (TR) protein, which binds a tetracycline respon-
sive element (TRE) on the promoter under doxycycline (dox, a semisynthetic derivate of 
tetracycline) free conditions and thereby block transcription. Upon addition of doxycy-
cline, the TR is released from the TRE, and the gene of interest will be expressed. There-
fore, HEK293 Flp-In/T-Rex cells were co-transfected with pcDNA5FRT/TO-mIL-31-
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RFP-3V5-3HA-his and pOG44, encoding Flp-In recombinase. After selection well-
growing clones were then grown to 80% confluency, the medium exchanged to serum-
free DMEM, and protein expression was induced with 200 ng/ml doxycycline. After 48h 
to 72h conditioned media were analyzed for mIL-31-RFP expression via Western blot-
ting. All selected clones expressed mIL31-RFP (Figure 11). Clone 6 showed highest lev-
els of mIL-31-RFP secretion. Already 48 hours following induction with doxycycline 
mIL-31-RFP secretion level of clone 6 (Figure 11 Lane 4) was higher than of clone 3 af-
ter 72h (Figure 11 Lane 2). For further protein production clone 6 was chosen. 
 
Figure 11: Analysis of conditioned media from HEK293 Flp-In/T-Rex mIL-31-RFP-3V5-
3HA-his clones Western Blot analysis of conditioned media from stably transfected HEK293 
mIL-31-RFP-3V5-3HA-6his clones under serum-free conditions. Protein expression was in-
duced with 200 ng/ml doxycycline. 
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4.2 Modification of mIL-6-RFP for application in vivo 
To transfer the previously described mIL-6-RFP (Wiesinger et al., 2009), consisting of 
the domains D1-D3 of murine gp130 and D1-D3 of murine soluble IL-6Rα, to an in vivo 
system, mIL-6-RFP was modified to facilitate serum detection, and sub-cloned into a 
tetracycline responsive vector system to regulate gene expression in specific tissues.  
4.2.1 Modification for serum detection 
For an increased sensitivity and the ability to specifically discriminate mIL-6-RFP from 
the soluble receptors sgp130 and sIL-6Rα present in the plasma of mice the V5/his tag 
was replaced with a 3V5-3HA tag module (Figure 12). This module is transferable to 
other proteins of interest and allows the use of α-HA/α-V5 based sandwich-ELISA to 
detect mIL-6-RFP in conditioned media or most importantly in plasma samples. The 
3V5-3HA tag module was amplified from pcDNA3.1 AlbuminWT-3V5-3HA (Tenten et 
al., 2013) via PCR, subsequently digested with EcoRI/PmeI, and cloned into Eco-
RI/PmeI digested pcDNA3 mIL-6-RFP-V5-his replacing V5-his with 3V5-3HA to cre-
ate pcDNA3.1 mIL-6-RFP-3V5-3HA.  
 
Figure 12: Schematic representation of mIL-6-RFP structure and exchange of tags Struc-
tural features of mIL-6-RFP. Arrows indicate binding of IL-6 to mIL-6-RFP with the dashed line 
indicating binding to a second mIL-6-RFP. Secretion of mIL-6-RFP-Fc is driven by the signal 
sequence of preprotrypsin (not shown). 
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Figure 13: Biologic activity of mIL-6-RFP-3V5-3HA (A) Primary murine hepatocytes were 
stimulated for 20 min with IL-6 (20 ng/ml) preincubated with control conditioned media 
(CM), mIL-6-RFP-V5-his or mIL-6-RFP-3V5-3HA with molar ratios of mIL-6-RFP:IL-6 as indicat-
ed (x mol). Cellular lysates were analyzed by Western blotting for phosphorylation of STAT3 
at Y705 (α-pSTAT3) and total STAT3 (α-STAT3) as a loading control. (B) Binding of either con-
trol, mIL-6-RFP-3V5-3HA or mIL-6-RFP-V5-his conditioned media to BSA-Sepharose or IL-6-
Sepharose. 
To address a possible influence of mIL-6-RFP tag exchange on biological activity, condi-
tioned media of transiently transfected HEK293 cells were pre-incubated with IL-6 for 
20 minutes to allow the fusion protein to bind to the cytokine. Primary murine hepato-
cytes were then stimulated for 20 minutes with either IL-6 alone or IL-6/mIL-6-RFP in 
different molar ratios. Conditioned media of mock-transfected HEK293 cells served as 
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control. Whole cell lysates were prepared, and STAT3 phosphorylation was analyzed. 
The stimulation with IL-6 alone or pre-incubated with control conditioned media leads 
to a prominent tyrosine phosphorylation of STAT3 (Figure 13A Lanes 4, 5). Treatment 
with IL-6 pre-incubated with increased volumes of mIL-6-RFP conditioned media with 
increasing molar ratios towards IL-6 resulted in a reduction of tyrosine phosphorylation 
of STAT3 (Figure 13A Lanes 6-8, 9-12). Already at equal molar ratios both mIL-6-RFP-
V5-his and mIL-6-RFP-3V5-3HA reduce STAT3 phosphorylation to nearly basal levels 
(Figure 13A Lanes 6, 10). To assess any influence on direct ligand binding, conditioned 
media of both variants of mIL-6-RFP were precipitated with immobilized IL-6 (Figure 
13B). The exchange of V5-his with 3V5-3HA did not alter binding of the fusion protein 
to IL-6 covalently bound to Sepharose (Figure 13B Lanes 10, 11). Only weak unspecific 
binding to BSA-Sepharose could be detected (Figure 13B Lanes 6, 7). PBS and condi-
tioned media from mock-transfected cells served as additional controls. Thus the ex-
change of the tag did not affect direct binding to IL-6 and IL-6 antagonizing activity of 
mIL-6-RFP. 
4.2.2 Cloning of the transgene expression vector  
 
Figure 14: Transgene expression vector pTRE-Tight-BI TREmod: modified tet responsive 
element; MCS: multiple cloning site; PminCMV: two mini CMV promoters, which lack the en-
hancer that is part of the complete CMV promoter. Both genes inserted into MCS I and MCS II 
will be responsive to the tTA and rtTA regulatory proteins in the Tet-Off and Tet-On systems, 
respectively (Clontech, 2010).  
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The pTRE-Tight-BI vector system is a well-suited system to generate transgenic mice 
which express a gene of interest in a tissue-specific and inducible manner (Figure 14). It 
contains a modified Tet response element (TREmod) flanked by two minimal CMV pro-
moters. This bidirectional Tet responsive promoter can be used to express either a re-
porter gene and one gene of interest, or two genes of interest. In both scenarios the Tet-
responsive promoter element needs to be induced by a doxycycline-activated reverse 
tetracycline Trans-Activator (rtTA) to initiate gene expression. To sub-clone the fusion 
protein into this system, two fragments of mIL-6-RFP-3V5-3HA were amplified via 
PCR from pcDNA3.1 mIL-6-RFP-3V5-3HA – a gp130 portion and an IL-6R-3V5-3HA 
portion, which were subsequently digested with KpnI/AgeI and AgeI/NotI, respectively. 
The digested fragments were subjected to three-fragment-ligation into a KpnI/NotI di-
gested pTRE-Tight-BI VEGF loxp/nlacZ vector replacing the VEGF loxp with mIL-6-
RFP-3V5-3HA, and thereby creating pTRE-Tight-BI mIL-6-RFP-3V5-3HA/nlacZ. This 
vector contains the nlacZ reporter gene encoding for β-Galactosidase with a nuclear 
localization signal. 
4.2.3 In vitro characterization of pTRE-Tight-BI mIL-6-RFP-3V5-3HA 
HepG2 cells were transiently transfected with combinations of pUHRT 62-1, encoding 
rtTA-M2 (Urlinger et al., 2000), and pTRE-Tight-BI mIL-6-RFP-3V5-3HA plasmids. 
Cells were grown to 80% confluency, the medium was exchanged to serum-free medi-
um, and cultured in the presence or absence of doxycycline for 48 h. Conditioned media 
were collected, whole cell lysates were prepared, separated by SDS-Page and analyzed 
for mIL-6-RFP-3V5-3HA expression and secretion via Western Blotting (Figure 15). 
mIL-6-RFP-3V5-3HA expression strictly depends on the presence of the rtTA, as trans-
fection of mIL-6-RFP-3V5-3HA encoding plasmids alone (Figure 15 Lanes 4, 8) or in 
combination with doxycycline (Figure 15 Lanes 5, 9) did not lead to any detectable fu-
sion protein. Co-transfection with the rtTA encoding plasmid already lead to low mIL-
6-RFP expression even without addition of doxycycline albeit with low secretion levels 
(Figure 15 Lanes 6, 10). Addition of doxycycline to co-transfected cells strongly induces 
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mIL-6-RFP expression and secretion (Figure 15 Lane 7, 11) demonstrating functionality 
of the expression system.  
 
Figure 15: In vitro characterization of pTRE-Tight-BI mIL-6-RFP-3V5-3HA Western Blot 
analysis of mIL-6-RFP-3V5-3HA and rtTA-M2 expression from transiently transfected HepG2 
cells in conditioned media (CM) and whole cell lysates (WCL).  
4.2.4 Generation of mIL-6-RFP transgenic mice  
For the generation of Tg(TRE:mIL-6-RFP) mice, pTRE-Tight-BI-lacZ-mIL-6-RFP-3V5-
3HA vector DNA was linearized with PacI  and injected into the pronucleus of fertilized 
eggs. The eggs were transferred into pseudo-pregnant recipient mice. To discriminate 
gp130 and IL-6Rα genes are located on chromosome 13 and chromosome 3 in the 
mouse genome, primer combinations that amplify either fused gp130/IL-6Rα fragments 
or vector elements like the bovine growth hormone poly adenylation signal (BGH pA) 
that are normally not encoded in the mouse genome, are ideally suited for genetic 
screening by PCR as they show no background signal (Figure 16A-C).  
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Figure 16: Genetic screening of mice following pronucleus injection (A) Schematic repre-
sentation of TREmod promoter (purple) mIL-6-RFP gene (orange) including substructure 
(green) and bovine growth hormone polyadenylation signal (BGH poly A) (grey) and localiza-
tion of sense (labels above mIL-6-RFP gene) and anti-sense (label below) primer binding sites 
(B) mIL-6-RFP transgene detection by PCR with genomic tail DNA as template with primer 
combinations depicted. (C) Expected PCR product size with the various primer combinations. 
(D) mIL-6-RFP transgene detection by PCR with genomic tail DNA as template with primer 
combination LB16/LB17. H2O and random mice tail DNA (-) served as negative control, pTRE-
Tight-BI-mIL-6-RFP plasmid (+) as positive control. 
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Genetic screening by PCR from tail biopsies of 39 newborn mice revealed 1 mice (Figure 
16D) where the DNA has integrated into the host genome (2.6% transgene submission). 
This founder mouse was used for subsequent transgenic breeding to establish a homo-
zygous mouse line Tg(TRE:mIL-6-RFP)1. A second pronucleus injection provided an-
other transgene positive mouse that was used for the generation of a second transgenic 
mouse line Tg(TRE:mIL-6-RFP)2, where genetic screening by PCR from 7 newborn 
mice revealed 1 mice (data not shown) where the DNA has integrated into the host ge-
nome (14.3% transgene submission). As the expression of mIL-6-RFP strictly depends 
on the presence of rtTA, both founder lines need to be crossed with mice that express 
rtTA in desired tissues. 
4.2.5 Double transgenic mice  
In this study, we sought to develop a system to temporally control the onset of transgene 
expression in a systemic or localized manner with mice as a model system. For systemic 
expression of the fusion protein Tg(TRE:mIL-6-RFP-3V5-3HA) mice were crossed with 
Tg(LAP:rtTA) mice. The latter express rtTA under control of the liver activator protein 
(LAP) promoter, which is mainly active in the liver and to a lesser extent in the kidney 
(Hasan et al., 2001, Schonig et al., 2002, Gallagher et al., 2003). The double transgenic 
animals are expected to produce mIL-6-RFP in hepatocytes of the liver followed by se-
cretion of the protein into the bloodstream for systemic availability. For a more local-
ized expression and specific use in renal disease models Tg(TRE:mIL-6-RFP-3V5-3HA) 
mice were crossed with Tg(Pod:rtTA) mice, where rtTA expression is under the control 
of a promoter, consisting of a 2.5-kb fragment of the human podocin gene NPHS2, 
which is mainly active in podocytes of the kidney (Shigehara et al., 2003). Each founder 
animal was crossed with rtTA mouse strains to establish different transgenic lines. For 
all litters PCR was used for identification of transgenic mice. 
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Figure 17: Tetracycline responsive system for mIL-6-RFP expression in vivo A schematic 
diagram showing the principle of induction of mIL-6-RFP and lacZ expression from genomi-
cally integrated pTRE-Tight-BI expression cassette in double transgenic mice. rtTA-M2, con-
stitutively expressed in corresponding tissues governed by the activity of either LAP- or Po-
docin-promoter, binds after complexing with doxycycline administered by drinking water to 
TREmod element, and induces the expression of both lacZ and mIL-6-RFP. 
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4.2.6 Analysis of Tg(LAP:rtTA/TRE:mIL-6-RFP) mice 
 
Figure 18: Analysis of Tg(TRE:mIL-6-RFP, LAP:rtTA)1F1 mice Transgene negative mice are 
marked in red (A) RT-PCR analysis for mIL-6-RFP mRNA from liver RNA from mice treated for 
14 days either with doxycycline or H2O. (B) RT-PCR analysis for β-Galactosidase mRNA from 
liver RNA samples from mice treated for 14 days either with doxycycline or H2O. (C) Western 
Blot analysis of liver lysates separated by SDS-Page and stained with α-V5 antibody. (D) 
Western Blot analysis of mouse serum separated by SDS-Page and stained with α-V5 anti-
body. 
In double transgenic mice Tg(TRE:mIL-6-RFP-3V5-3HA, LAP:rtTA) both the fusion 
protein and β-Galactosidase are expressed under the transcriptional control of the rtTA 
controlled promoter. rtTA expression is driven through LAP promoter, which is mostly 
hepatocyte-specific, but also drives expression in proximal tubular cells of the kidney to 
a lesser extent. Since hepatocytes exhibit a high synthetic capacity, mIL-6-RFP should be 
secreted into the serum in high amounts. Therefore RNA, liver lysates and serum of 
doxycycline treated mice were examined for mIL-6-RFP and rtTA expression. Although 
there was mRNA of mIL-6-RFP-3V5-3HA (Figure 18A) and β-Galactosidase (Figure 
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18B) detectable, mIL-6-RFP protein could be detected neither in liver lysates (Figure 
18C) nor in serum (Figure 18D) of any Tg(TRE:mIL-6-RFP-3V5-3HA, LAP:rtTA) mice 
tested. 
 
Figure 19: Hydrodynamic co-transfection of pTRE-Tight-BI mIL-6-RFP + nlacZ & pEGFP 
into doxycycline treated Tg(LAP:rtTA) mice (A) X-Gal staining and (B) Immunofluores-
cence from serial sections of liver tissue 
As it was shown in the in vitro characterization of the vector system (Chapter 4.2.3) the 
expression strictly depends on rtTA expression. Therefore we hydrodynamically co-
transfected Tg(LAP:rtTA) mice with pTRE-Tight-BI-mIL-6-RFP-3V5-3HA/nlacZ and 
pEGFP-N1. In serial sections of the liver only low and mosaicism-like expression of β-
Galactosidase is detectable (Figure 19A), whereas GFP is strongly expressed throughout 
the liver (Figure 19B). 
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4.2.7 Analysis of Tg(Pod:rtTA/TRE:mIL-6-RFP) mice 
 
Figure 20: Analysis of Tg(TET:mIL-6-RFP.tg1/pod:rtTA)2F1 mice (A) β-Galactosidase ex-
pression in the kidney sections of Tg(TET:mIL-6-RFP.tg1/pod:rtTA) mice. Doxycycline (2 
mg/ml) was administered in drinking water for 14 days. (B) Western Blot analysis of whole 
kidney lysates from doxycycline treated mice.  
In Tg(TRE:mIL-6-RFP-3V5-3HA, Pod:rtTA) mice transgene expression is controlled by 
podocyte specific rtTA expression. Therefore tissue sections and kidney lysates of 
doxycycline-treated mice were examined for β-Galactosidase or mIL-6-RFP expression, 
respectively. X-Gal staining showed an expression pattern of β-Galactosidase, that was 
localized predominantly to the periphery of glomeruli (Figure 20A). There was no mIL-
6-RFP detectable in whole kidney lysates (Figure 20B) of any Tg(TRE:mIL-6-RFP-3V5-
3HA, Pod:rtTA) mice tested. 
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4.3 Re-Engineering of mIL-6-RFP-3V5-3HA 
As the initial approach to establish mIL-6-RFP as an in vivo research tool in a transgenic 
mouse model was not successful due to the lack of any detectable mIL-6-RFP protein in 
either serum or tissues, another approach was considered. Therefore we thought to fur-
ther modify mIL-6-RFP by the addition of the constant fragment of an antibody to allow 
protein purification through affinity chromatography and to improve its pharmacoki-
netics. To enhance mammalian expression the cDNA was codon optimized and intro-
duced into expression vectors suitable for transient or stable expression and finally, as 
receptor fusion proteins are encoded by a single gene, into vectors suitable for gene 
transfer approaches.  
4.3.1 Generation of mIL-6-RFP-Fc 
mIL-6-RFP-Fc-3V5-3HA (Figure 21A) was generated by adding an engineered mIgG2a 
Fc-fragment (hinge-CH2-CH3) followed by a transferable 3V5-3HA tag for detection 
and quantification to the C-terminus of our previously reported receptor fusion protein 
mIL-6-RFP for the inhibition of human, rat and murine IL-6. The Fc region of mouse 
IgG2a normally mediates high antibody-dependent cellular cytotoxicity (ADCC) and 
complement-dependent cytotoxicity (CDC). To reduce its cytotoxicity, mIgG2a-Fc was 
engineered by mutating the amino acids that are critical for Fcγ receptor (FcγR) and 
C1Q complex binding of the complement system (Steurer et al., 1995). The Fc fragment 
facilitates purification through protein A/G affinity chromatography and is expected to 
increase serum half-life of the recombinant protein through interaction with the neona-
tal Fc receptor (FcRn) (Kuo and Aveson, 2011). Moreover, the Fc-fragment enforces 
dimerization of the fusion protein through disulfide bond formation increasing its 
avidity towards IL-6. The dimer is perfectly tailored for adapting the conformation of 
the hexameric IL-6 receptor complex required for high-affinity IL-6-binding (Figure 
21B). 
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Figure 21: Design, characterization and structural model of mIL-6-RFP-Fc (A) Schematic 
representation of the structural features of mIL-6-RFP-Fc. Arrows indicate binding of IL-6 to 
mIL-6-RFP-Fc with the dashed line indicating binding to a second mIL-6-RFP-Fc resulting in 
the formation of a complex in analogy to the hexameric IL-6 receptor complex (shown in B). 
Secretion of mIL-6-RFP-Fc is driven by the signal sequence of preprotrypsin (not shown) (B) 
Schematic representation (left panel) and structural model (right panel) of the (IL-6)2(mIL-6-
RFP-Fc)2 inhibitory complex. The structural model is based on the crystal structures of the 
human hexameric IL-6 signaling complex (PDB: 1P9M), human IL-6Rα (PDB: 1N26), and the 
hinge region, CH2 domain and CH3 domain of murine IgG2A (PDB: 1IGT). 
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4.3.2 Codon Optimization of mIL-6-RFP-Fc 
The cDNA encoding mIL-6-RFP-Fc was optimized for gene delivery in mice by replac-
ing 32% of the codons for those being preferred in mice (Figure 22). In addition, poten-
tial internal inhibitory motifs, AT-rich instability motifs, repeat sequences, internal pol-
yadenylation sites, as well as splice donor and acceptor sites were eliminated. The fully 
synthesized cDNA coding for mIL-6-RFP-Fc was flanked with restriction sites to facili-
tate sub-cloning into the pcDNA3, pcDNA5 and pTZ18R-PEPCK vector systems for 
transient, stable expression and gene transfer approaches, respectively. The transfer vec-
tor pMA-mIL-6-RFP-Fc-3V5-3HA containing the optimized mIL-6-RFP-Fc was syn-
thesized by GeneArt (Regensburg). 
 
Figure 22: Codon quality and %GC content plot  Comparison of codon quality and %GC 
content of the non-optimized vs. optimized mIL-6-RFP-Fc cDNA sequence.  
4.3.3 Cloning of expression vectors 
The optimized cDNA for mIL-6-RFP-Fc was excised from the transfer vector pMA-
mIL-6-RFP-Fc-3V5-3HA with HindIII/NotI and transferred through direct restriction 
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cloning into HindIII/NotI digested pcDNA3 and pcDNA5/FRT/TO vectors to generate 
the expression vectors pcDNA3-mIL-6-RFP-Fc-3V5-3HA, pcDNA5/FRT/TO-mIL-6-
RFP-Fc-3V5-3HA, respectively. For gene delivery approaches we chose to adapt a vector 
system that was previously described to successfully overexpress sgp130-Fc, a fusion 
protein specifically targeting IL-6 trans-signaling, in transgenic mouse models (Rabe et 
al., 2008). The optimized mIL-6-RFP-Fc cDNA was excised from pMA-mIL-6-RFP-Fc-
3V5-3HA by XhoI digestion and cloned into XhoI digested pTZ-PEPCK-bglob.intron-
sgp130-Fc-b.glob.polyA vector thereby creating PTZ-PEPCK-b.glob.intron-mIL-6-RFP-
Fc-3V5-3HA-b.glob.polyA. 
4.3.4 Comparative expression of optimized mIL-6-RFP-Fc in vitro 
 
Figure 23: Comparative transient expression of mIL-6-RFP-Fc Western blot analysis (left 
panel) of equal volumes of conditioned media harvested from (A) HepG2 and (B) muHepa 
cells transiently transfected with optimized (opt) or non-optimized (non-opt) mIL-6-RFP-Fc 
expression plasmids after the indicated time points using an antibody directed against the 
V5-epitope (α-V5). Bar charts show relative expression of mIL-6-RFP-Fc from densitometric 
analyses of Western blots. For comparison, densitometric levels from the secretion of non-
opt mIL-6-RFP-Fc at 72 hours were set to 1. Results of five independent experiments are pre-
sented (means ± SD).  
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To evaluate the effects of codon optimization on protein expression levels of mIL-6-
RFP-Fc, murine hepatocarcinoma cells (muHepa) and HepG2 cells were transiently 
transfected with expression vectors encoding for either the non-optimized or optimized 
cDNA for mIL-6-RFP-Fc. Over time increasing amounts of the recombinant protein 
were detected in conditioned media (Figure 23 A + B). Compared to the original cDNA 
the optimized cDNA yielded an about 2.5-fold increase in protein secretion in HepG2 
over 72 hours (Figure 23A Lane 3 vs. 6) and a 1.6-fold increase in muHepa cells over 72 
hours (Figure 23B Lane 3 vs. 6). 
4.3.5 Generation of single clone stable producer cell lines 
 
Figure 24: mIL-6-RFP-Fc expression in stably transfected HEK 293 Flp-In/T-Rex single 
cell clones Western Blot analysis of conditioned media from stably transfected HEK 293 Flp-
In/T-Rex clones. Equal volumes of conditioned media harvested from different clones were 
loaded and separated by SDS-Page. 
For continuous protein production a stable producer cell line was to be generated. We 
chose again the HEK293 Flp-In/T-Rex cell system for targeted integration of the gene of 
interest together with the ability to induce protein expression. HEK293 Flp-In/T-Rex 
cells were co-transfected with pcDNA5/FRT/TO-mIL-6-RFP-Fc-3V5-3HA and pOG44. 
Transfected cells were selected by addition of 200 μg/ml hygromycin B and seeded at 
low density to select single cell clones. Well-growing clones were then grown to 80% 
confluency, the medium exchanged to serum-free DMEM, and protein expression was 
induced with 200 ng/ml doxycycline. After 72h conditioned media were analyzed for 
mIL-6-RFP-Fc expression via Western Blotting. All selected clones showed expression 
of the receptor fusion protein (Figure 24). Clone 6 showed the highest secretion levels 
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for mIL-6-RFP-Fc (Figure 24 Lane 3) and was therefore chosen for continuous protein 
production. 
4.3.6 mIL-6-RFP-Fc purification and characterization 
 
Figure 25: Purified mIL-6-RFP-Fc and Rf-value based calculation of molecular mass  
Purified mIL-6-RFP-Fc was analyzed by 7.5% SDS/PAGE. Purity and identity was determined 
by staining with Coomassie brilliant blue and Western blotting, respectively, under non-
reducing and reducing conditions. The molecular mass of mIL-6-RFP-Fc was determined by 
calculating the Rf of five marker proteins and inserting the Rf of mIL-6-RFP-Fc monomer and 
dimer into the equation for the linear regression. 
To calculate the molar mass of mIL-6-RFP-Fc in its monomeric and dimeric form puri-
fied mIL-6-RFP-Fc was analyzed by SDS-PAGE under non-reducing and reducing con-
ditions, then stained with Coomassie and destained to visualize the protein bands of the 
marker and purified mIL-6-RFP-Fc proteins (Figure 25 left panel). The gel was analyzed 
to obtain the Rf values for each band. A plot of log MW versus Rf was generated (Figure 
25 right panel). Apparent molecular masses of 270 kDa for the dimer and 135 kDa for 
the monomer have been calculated. 
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4.3.7 Inhibitory activity in vitro 
 
Figure 26: mIL-6-RFP-Fc mediated inhibition of IL-6 induced STAT3 phosphorylation  
(A) muHepa cells were stimulated for 20 min with IL-6 (20 ng/ml), mIL-6-RFP-Fc (RFP) or IL-6 
(20 ng/ml) preincubated with mIL-6-RFP-Fc (RFP) at concentrations ranging from 22.25 to 
1335 ng/ml for 15 min corresponding to molar ratios of mIL-6-RFP-Fc:IL-6 as indicated (x 
mol). Cellular lysates were analyzed by Western blotting for phosphorylation of STAT3 at 
Y705 (α-pSTAT3) and total STAT3 (α-STAT3) as a loading control. (B) muHepa cells were pre-
treated for 120 min with a 10-fold molar excess of mIL-6-RFP-Fc (1335 ng/ml) and subse-
quently stimulated with IL-6 (20 ng/ml) for 20 min. Phosphorylation of STAT3 was analyzed 
as described in A.  
To characterize the bioactivity of mIL-6-RFP-Fc, muHepa cells were stimulated with 
mIL-6 that had been pre-incubated with purified mIL-6-RFP-Fc in molar ratios ranging 
from 0.2 to 10 (Figure 26A). As a read-out of IL-6 activity tyrosine phosphorylation of 
STAT3 was analyzed. Complete inhibition of IL-6 was already achieved at about 
equimolar concentrations of mIL-6-RFP-Fc and IL-6 (Figure 26A Lane 10). In the next 
experiment, mIL-6-RFP-Fc and IL-6 were not pre-incubated, but cells were pretreated 
with mIL-6-RFP-Fc (Figure 26B). Subsequent addition of IL-6 did not elicit phosphory-
lation of STAT3 over a prolonged period of time indicating that even in direct competi-
4 Results 79 
tion with the cell surface receptors mIL-6-RFP-Fc neutralizes IL-6 immediately and 
completely. 
 
Figure 27: mIL-6-RFP-Fc inhibits IL-6 dependent cell proliferation Equal numbers of 
Ba/F3-mgp130/mIL-6Rα cells were incubated with a constant amount of IL-6 (37 pM) and 
serial 2-fold dilutions of either mIL-6-RFP-Fc (starting concentration 3.9 nM) or mIL-6-RFP 
(starting concentration 3.4 nM). After 60 h of incubation, viable cells were quantified using a 
colorimetric XTT assay. Data shown are means ± SD (n=6). 
After showing that mIL-6-RFP-Fc inhibits IL-6 dependent STAT3 phosphorylation in 
muHepa cells, we wanted to compare the inhibitory activity of mIL-6-RFP-Fc to the 
previously described mIL-6-RFP. We chose the murine pre-B-cell line Ba/F3, which 
does not express murine gp130 and murine IL-6Rα, and only proliferates in the pres-
ence of IL-3. By stable transfection with cDNA encoding mgp130 and mIL-6Rα we gen-
erated a Ba/F3-mgp130/mIL-6Rα cell line that proliferates IL-6 dependently, and is 
therefore well suited to compare the inhibitory activities of mIL-6-RFP and mIL-6-RFP-
Fc. IL-6-dependent proliferation of Ba/F3-mgp130/mIL-6Rα cells was inhibited in a 
concentration-dependent manner by both inhibitors. However, mIL-6-RFP- Fc’s inhibi-
tory activity was one order of magnitude higher compared to the non-optimized version 
mIL-6-RFP (Figure 27; IC50 mIL-6-RFP-Fc: 3.3x10-5 μM, IC50 mIL-6-RFP: 3.8x10-4 
μM) which is in agreement with the higher avidity of mIL-6-RFP-Fc as proposed in our 
model (Figure 21B) and with the increase of the activity of the IL-6 trans-signaling in-
hibitor sgp130 upon Fc fusion (Jostock et al., 2001). 
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4.4 In vivo application of mIL-6-RFP-Fc 
The continuous mIL-6-RFP-Fc production with subsequent purification through affini-
ty chromatography allows the use of recombinant protein for determination of its 
pharmacokinetics in animals and additionally the evaluation of its therapeutic potential 
in vivo. 
4.4.1 Pharmacokinetics of recombinant mIL-6-RFP-Fc 
 
Figure 28: Pharmacokinetics of recombinant mIL-6-RFP-Fc (A) Western blot analysis of 
mIL-6-RFP-Fc in mouse serum samples (2 μl serum/lane) obtained at the indicated time 
points following administration of indicated amounts of mIL-6-RFP-Fc either intravenously 
(i.v.), intraperitoneally (i.p.) or subcutaneously (s.c.) using an antibody directed against the 
V5-epitope (α-V5). (B) Left: mIL-6-RFP-Fc serum concentrations over time following intraperi-
toneal administration of the indicated amounts of recombinant protein as determined by an 
ELISA based on capture and detection of the HA- and V5-epitopes, respectively. Depicted are 
individual animals. Right: Statistical evaluation by normalization of each animals’ values on 
its 2 h serum level (n=3). Calculated time constant: t1/2 = 3.5 h.  
To establish its bioavailability in a mammalian system, mIL-6-RFP-Fc was administered 
to mice 1 μg intravenously (i.v.), 1.5 μg intraperitoneally (i.p.) and 1.5 μg subcutaneous-
4 Results 81 
ly (s.c.) and recovered via blood sampling. For i.v. injection a lower amount was chosen 
because a higher recovery was expected upon direct administration to the blood stream.. 
As determined by Western blot analysis of serum samples (Figure 28A), the i.v. and i.p. 
routes gave rise to the highest systemic levels with the latter resulting in prolonged se-
rum detectability with no signs of major degradation of the fusion protein (Figure 28A 
Lane 3-4; Lane 7-9). Subcutaneous application did not result in significant plasma levels 
(Figure 28A Lane 11-14), which might be explained by the known slow-onset and pro-
longed pharmacokinetics of this route. It should be noted that a non-optimized, non-Fc-
containing variant of mIL-6-RFP (Wiesinger et al., 2009) was successfully applied s.c. 
for local IL-6 antagonism in a cutaneous tumor model (Schroeder et al., 2014). To fur-
ther characterize the pharmacokinetics of mIL-6-RFP-Fc, different amounts were inject-
ed i.p. followed by quantitative serum ELISA directed against the epitope tags. At the 
highest amount (40 μg) applied in one single administration, mIL-6-RFP-Fc could be 
detected in serum for up to 48 h (Figure 28B left diagram). Normalization of the differ-
ent animals’ serum mIL-6-RFP-Fc levels on their respective 2 h value, allowed for statis-
tical analysis and determination of a time constant (t1/2 = 3.5 h) across the amounts of 
protein spiked (Figure 28B, right diagram). The observed half-life is identical with the 
initial clearing determined for an IL-2-Fc fusion protein harbouring the same Fc-
fragment (mIgG2a) (Zheng et al., 1999). 
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4.4.2 mIL-6-RFP-Fc inhibits IL-6-induced STAT3 and ERK phosphorylation in 
vivo 
 
Figure 29: Coincubation of IL-6 with mIL-6-RFP-Fc inhibits IL-6-dependent STAT3 and 
ERK phosphorylation in vivo  Western blot analysis of mouse liver lysates prepared 15 min 
following intravenous administration of either PBS, IL-6 (100 ng) or preincubated IL-6/mIL-6-
RFP-Fc-complexes (100 ng/3.5 μg, corresponding to a molar ratio 1:5, incubation for 30 min). 
To determine the efficacy of mIL-6-RFP-Fc in mice we established a model of IL-6-
stimulated STAT3 and ERK1/2 phosphorylation in liver and kidney tissues. In analogy 
to the in vitro experiments, mIL-6-RFP-Fc was either pre-incubated with IL-6 (Figure 
29) or the proteins were administered sequentially (Figure 30). In both scenarios mIL-6-
RFP-Fc significantly reduced IL-6 downstream signaling. Pretreatment with 40 μg (70x 
molar excess) of mIL-6-RFP-Fc i.p. for 45 min attenuated STAT3 and ERK1/2 phos-
phorylation by 12 and 63 % in the liver and by 80 and 50 % in the kidney, respectively 
(Figure 30). Collectively, these data established mIL-6-RFP-Fc as a potent therapeutic 
agent for the inhibition of IL-6 in vitro and in vivo. Phosphorylation was assessed by the 
ratio of phosphorylated versus total STAT3 or ERK1/2 (Figure 30). Variations of total 
STAT3 levels might be due to the fact that activated STAT3 induces its own gene ex-
pression (Hutchins et al., 2013, Nagayama et al., 2014). 
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Figure 30: mIL-6-RFP-Fc pretreated mice exhibit reduced IL-6 dependent STAT3 
activation (Left) Representative Western blots of mouse liver and kidney lysates prepared 15 
min following intravenous administration of either PBS or IL-6 (100 ng). Mice were pretreated 
for 45 min with PBS or mIL-6-RFP-Fc i.p. at dosages of 4, 12 or 40 μg, corresponding to molar 
IL-6/mIL-6-RFP-Fc (RFP) ratios as indicated. Phosphorylated STAT3 (α-pSTAT3), phosphory-
lated ERK1/2 (α-pERK1/2), total STAT3 (α-STAT3) and total ERK1/2 (α-ERK1/2) were detected. 
GAPDH and HSP70 served as loading controls. (Right) Statistical evaluation of experiments 
depicted in D. Data shown are means ± SD. *p≤0.05, one-sided t-test (n=2 for PBS i.v. stimu-
lated groups; n=5 for PBS i.p. / IL-6 i.v.; n=3 for RFP 7x i.p. / IL-6 i.v.; n=3 for RFP 20x i.p. / IL-6 
i.v.; n=4 for RFP 70x i.p. / IL-6 i.v.). Because of variations in STAT3 expression levels, pSTAT3 
was normalized relative to total STAT3. Similarly, pERK1/2 was normalized relative to total 
ERK1/2. 
4.4.3 mIL-6-RFP-Fc gene delivery by hydrodynamic transfection 
Although anti-cytokine therapy through application of recombinant protein has been 
shown to be effective, protein production is expensive and tedious. We argued that a 
gene therapeutic approach, where small amounts of a delivered plasmid generates sub-
stantial protein levels by the recipient himself, might be much more efficient. mIL-6-
RFP-Fc is encoded by a single gene and therefore ideally suited for gene delivery. In or-
der to achieve high systemic levels of circulating mIL-6-RFP-Fc we used the method of 
hydrodynamic plasmid delivery via the tail vein, which mainly results in transfection of 
the liver and to a much lower extent of the kidney and other organs (Liu et al., 1999). 
The phosphoenolpyruvate carboxykinase (PEPCK) promoter was chosen because it is 
active in the liver and generates high systemic levels of soluble proteins (Beale et al., 
1992, Rabe et al., 2008). Following gene delivery, mIL-6-RFP-Fc was detected in liver 
tissue (Figure 31A) and serum (Figure 31B). The concentration of expressed protein in 
the liver correlated well with the amount of plasmid used for transfection (i.e. 10 and 37 
μg/animal, respectively). Using the latter amount, a mIL-6-RFP-Fc serum level at 24 h of 
1.3 ± 1.5 μg/ml (mean ± SD; n=4) was achieved, thus corresponding to the 2 h and 12-
24 h levels upon singular i.p. spiking of 4 and 40 μg of mIL-6-RFP-Fc, respectively 
(Figure 28B). Subsequently, 37 μg of plasmid per animal were used for hydrodynamic 
transfection throughout all experiments. Analysis of liver sections of mice that were 
simultaneously transfected with plasmid encoding mIL-6-RFP-Fc and eGFP revealed 
that a single cell either expresses the fusion protein or eGFP but rarely both (Figure 
31C). This finding emphasizes the advantage of a single gene construct such as receptor 
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fusion proteins over proteins encoded by multiple genes such as antibodies for gene 
transfer approaches. 
 
Figure 31: Hydrodynamics-based transfection of PEPCK-mIL-6-RFP-Fc (A) Western blot 
analysis of liver lysates from mice hydrodynamically transfected with control vector (eGFP) 
lacking the epitopes or mIL-6-RFP-Fc using an antibody directed against the V5-epitope of 
mIL-6-RFP-Fc (α-V5). Amounts of plasmid transfected were as indicated. Mice were sacrificed 
24 hours post transfection. As a negative control, a mouse treated with transfection agent 
without plasmid is shown. Detection of HSP70 served as a loading control (α-HSP70). (B) mIL-
6-RFP-Fc serum concentrations as determined by ELISA at time points indicated. n=4 ani-
mals; subsequently analyzed in (D). (C) Immunofluorescence of liver cryosections 24 hours 
post hydrodynamic gene delivery. Cotransfection with expression vectors encoding mIL-6-
RFP-Fc (as detected by α-HA, red) and eGFP (green) was performed. As a negative control, a 
mouse treated with transfection agent without plasmid is shown. (D) qRT-PCR of liver acute 
phase mRNAs 24 hours after hydrodynamic delivery of 37 μg of either control plasmid or 
mIL-6-RFP-Fc-endocing plasmid. SAA1, serum amyloid A; A2M, α2-macroglobulin. Data were 
normalized and calculated using the housekeeper GAPDH and the ΔΔCT method (Livak and 
Schmittgen, 2001). X-fold expression relative to mean of healthy normal mice. n=4 (mIL-6-
RFP-Fc) and n=5 (eGFP) animals/group. Box plots, whiskers indicating minimal to maximal 
values, *p≤0.05, one-sided t-test. 
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The bioactivity of mIL-6-RFP-Fc administered through gene transfer could be directly 
confirmed by the suppression of hepatic acute phase protein production which had been 
induced by the invasive transfection procedure. Expression of mRNA for serum amyloid 
A1 (SAA1) was significantly reduced and expression of mRNA for α2-macroglobulin 
(A2M) showed a trend of a reduction (Figure 31D). Both molecules are known to be 
governed by IL-6 (Sander et al., 2010). A trend for slightly increased IL-6 mRNA levels 
in the mIL-6-RFP-Fc treated group might reflect compensatory IL-6 production (Figure 
31D). The fact that SAA1 is not completely suppressed in this model might be potential-
ly explained by other SAA1-governing cytokines such as IL-1 and TNF being released 
following hydrodynamic transfection. 
4.4.4 mIL-6-RFP-Fc pharmacokinetics after gene delivery 
 
Figure 32: mIL-6-RFP-Fc pharmacokinetics following mIL-6-RFP-Fc gene delivery Serum 
levels of mIL-6-RFP-Fc from 4 mice (#1-#4) over time following hydrodynamic transfection 
with 37 μg plasmid. Western blot using an antibody directed against the V5-epitope (α-V5, 
upper panel) and corresponding quantification by ELISA (lower panel). ctrl, mouse transfect-
ed with empty vector. 
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To assess the usefulness of the hydrodynamic transfection approach for disease models, 
the pharmacokinetics of mIL-6-RFP-Fc were evaluated in more detail. mIL-6-RFP-Fc 
was detected in serum for up to one week after gene transfer, again with no signs of deg-
radation. Average serum levels of 1.6 μg/ml (±1.6 SD; n=4) mIL-6-RFP-Fc were 
achieved for at least 48 h (Figure 32), indicating continuous synthesis as opposed to sin-
gular spike and turnover (Figure 28). 
4.4.5 Model of ischemia and reperfusion injury in the kidney 
 
Figure 33: Experimental outline of the used acute kidney injury model by ische-
mia/reperfusion Bilateral (bilat.) renal ischemia-reperfusion (I/R, 33 min of ischemia) per-
formed 24 hours following hydrodynamic transfection (hydrodyn. transf.) of 37 μg mIL-6-
RFP-Fc or 37 μg empty vector. Serum levels of mIL-6-RFP-Fc was measured at 20 h post hy-
drodynamic transfection. Serum creatinine was assessed 5 days prior to gene delivery and at 
sacrifice.  
To assess the therapeutic potential of mIL-6-RFP-Fc produced via gene delivery in a 
relevant disease model we applied a model of acute kidney injury (AKI) by transient 
bilateral renal ischemia for 33 minutes followed by reperfusion for 24 hours (I/R). This 
well-established model of tubular cell necrosis (Wei and Dong, 2012) has been previous-
ly demonstrated to depend critically on IL-6 (Jones et al., 2015). Injury is significantly 
reduced in IL-6-/- mice and can also be alleviated by the adoptive transfer of IL-6-/- bone 
marrow or by treatment with IL-6 neutralizing antibodies, resulting in improved renal 
serum and histological parameters (Patel et al., 2005, Kielar et al., 2005). The current 
experimental design is outlined in Figure 33. Mice with detectable mIL-6-RFP-Fc serum 
levels (0.25 - 4.5 μg/ml; mean 1.5 μg/ml ± SD 1.5) at 20 h post hydrodynamic transfec-
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tion or equally treated mice having received control vector were subjected to bilateral 
I/R of 33 minutes duration at 24 h and sacrificed at 48 h for further organ analysis. 
 
Figure 34: mIL-6-RFP-Fc blocks acute phase protein synthesis in the I/R injury model 
qRT-PCR of acute phase mRNAs from liver of sacrificed mice as calculated relative (x-fold) to 
mean of healthy control mice using housekeeper GAPDH and the ΔΔCT method. Expression 
of both acute phase proteins by mIL-6-RFP-Fc transfection is significantly reduced (red bars) 
in comparison to control vector (grey bars). Nonlinear regression analysis revealed that sup-
pression of SAA1 and A2M correlates with serum mIL-6-RFP-Fc levels. Red bar, mIL-6-RFP-Fc; 
grey bar, empty vector. All data are from n=8 animals/group, shown as means ± SD and/or 
single values, *p≤0.05, **p≤0.01, ***p≤0.001 one-sided t-test. 
Successful transfection and biological activity of mIL-6-RFP-Fc was confirmed by sup-
pressed hepatic (Figure 34A) SAA1 and (Figure 34B) A2M mRNAs, which also correlat-
ed with the 20 h serum level of mIL-6-RFP-Fc (Figure 34A+B, right panels).  
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Figure 35: mIL-6-RFP-Fc ameliorates kidney damage (A) Increased serum creatinine fol-
lowing I/R is significantly reduced by prior transfection with mIL-6-RFP-Fc. Verification of t-
test results by ANOVA with Tuckey multiple group analysis revealed an overall p≤0.0001 and 
an identical significance level of ≤0.01 for I/R control versus mIL-6-RFP-Fc. (B) Transcription of 
the tubular injury marker NGAL in both kidneys as assessed using housekeeper GAPDH and 
the ΔΔCT method (Livak and Schmittgen, 2001), indicating the significant mitigation of renal 
injury upon hydrodynamic transfection of mIL-6-RFP-Fc (red bars) compared to empty vector 
(grey bars). (C) Representative renal tissue sections, original magnifications, x200. Dotted 
lines, representative renal tubules. Normal healthy kidney showing homogeneous basophilic 
and eosinophilic staining of the cytoplasm and of the apical brush border membrane, re-
spectively. Following I/R, tubular dilatation/atrophy (arrowheads), loss of the brush border 
(arrow), tubular necrosis (asterisk) and leukocyte infiltration (L) ensue, the degree of which is 
mitigated following transfection with mIL-6-RFP-Fc. Far right: statistical analysis of tissue 
injury score for the right kidney (left kidney not assessed). Red bar, mIL-6-RFP-Fc; grey bar, 
empty vector. All data are from n=8 animals/group, shown as means ± SD and/or single val-
ues, *p≤0.05, **p≤0.01, ***p≤0.001 one-sided t-test. 
In line with the previous studies (Patel et al., 2005, Kielar et al., 2005), we observed simi-
lar beneficial effects on renal endpoints. Serum creatinine (Figure 35A), intrarenal 
mRNA synthesis of the acute kidney injury marker neutrophil gelatinase-associated 
lipocalin (NGAL)/lipocalin-2 (Lcn2) (Ko et al., 2010, Nickolas et al., 2008) (Figure 35B) 
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and histologic tubular injury scoring (Figure 35C) were significantly reduced following 
transfection with mIL-6-RFP-Fc. These data are also in line with another report in 
which IL-6-/- mice were protected in the initial phase of a mercury-induced proximal 
tubular injury model (Nechemia-Arbely et al., 2008). It must be noted that the renal 
functional and renal histologic endpoints of the mIL-6-RFP-Fc group exhibited a com-
paratively wide variance (Figure 35A, C). This is in agreement with published data on 
this complex acute kidney injury model (Kielar et al., 2005). By combining the data from 
the hydrodynamic transfections of 16 individual animal described herein (Figure 31B 
n=4, Figure 32 n=4, Figure 34 n=8), a very consistent mean serum expression level of 
mIL-6-RFP-Fc within the first 20-48 h of 1.5 μg/ml; ± SD 1.4 can be inferred. 
Collectively, the consistent reduction of the hepatic acute phase response in both the 
hepatic transfection and the I/R model (Figure 31D and Figure 34, respectively) and the 
significant – though variant – benefit of renal endpoints in I/R (Figure 35) establish en-
dogenous expression of mIL-6-RFP-Fc via gene transfer as an effective treatment in mu-
rine disease models. 
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5 Discussion 
5.1 Biochemical characterization of mIL-31-RFP 
In the first part of this study we developed a novel receptor fusion protein for the inhibi-
tion of murine IL-31. The receptor fusion protein mIL-31-RFP consists of domains D1-
D4 of murine OSMR connected with a flexible polypeptide linker to domains D1-D2 of 
mIL-31R. Starting with our previously cloned mOSM-RFP (Brolund et al., 2011), we 
exchanged the domains D2+D3 of murine gp130 with the CBM of murine IL-31R, 
transforming the fusion protein from an OSM-specific to an IL-31-specific cytokine 
inhibitor (Figure 7). An additional tag exchange from flag to a 3V5-3HA module al-
lowed reliable quantification with an ELISA directed against the two triple tags. As pri-
mary murine keratinocytes as well as PAM212 cells did not respond to IL-31 stimula-
tion before and after IFN-γ priming, which is known to upregulate IL-31R expression 
(Figure 8), we established a reliable cell system for the analysis of IL-31-dependent sig-
nal transduction by stably transfecting MEF cells with murine full-length IL-31R cDNA, 
rebuilt by PCR-based fusion of exon fragments (Figure 9). MEF mIL-31R cells allowed 
us to analyze IL-31 signaling, and assay the inhibitory activity of mIL-31- 
RFP. As expected mIL-31-RFP is a potent inhibitor of IL-31 induced STAT3 phosphory-
lation (Figure 10).  
5.1.1 Specificity of mIL-31-RFP 
OSMR acts as the common receptor subunit involved in the formation of the heterotri-
meric signaling complex for both IL-31 and OSM, with either IL-31R or gp130 as the 
second receptor subunit, respectively. In regards to cytokine specificity, the question 
arises whether mIL-31-RFP is able to at least partially inhibit OSM signaling due to the 
N-terminal domains D1-D4 of murine OSMR. Even a 10-fold molar excess of mIL-31-
RFP did not inhibit OSM bioactivity on MEF cells (Figure 10). This suggests that the 
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affinity between the OSMR component of the mIL-31-RFP and murine OSM is very low 
and is not sufficient for high-affinity binding over the membrane bound full-length re-
ceptors OSMR and gp130, which are both present on MEF cells.  
5.1.2 Potential use of mIL-31-RFP 
The contribution of IL-31 to atopic dermatitis was first discovered in a mouse model 
with transgenic IL-31 overexpression. Thus IL-31 has been implicated as a key factor in 
pruritic skin and other allergic diseases like asthma (Dillon et al., 2004, Neis et al., 2006, 
Sonkoly et al., 2006). Recent evidence shows its direct involvement with neurons in dor-
sal root ganglia (Bando et al., 2006).  
For the inhibition of human IL-31 the fusion protein OSMR-L-GPL (Venereau et al., 
2010) was constructed following the design principles of hIL-6-RFP (Ancey et al., 2003). 
As there exists a strict species specifity regarding receptor interaction of human and 
murine IL-31 (Broxmeyer et al., 2007) OSMR-L-GPL cannot be used in murine models 
of atopic dermatitis. Therefore mIL-31-RFP will be a useful tool to decipher the role of 
murine IL-31 in mouse models of pruritic skin diseases and the further dissection of 
cytokine signaling networks. Although there already exists an antibody targeting murine 
IL-31 (Grimstad et al., 2009), mIL-31-RFP allows refined targeting of cytokines in mu-
rine disease models. Because of its monogenic nature, mIL-31-RFP is well suited for 
transgenic or gene delivery approaches. Transfer vectors can be designed for temporal 
and spatial expression of mIL-31-RFP through organ- or tissue-specific promoters so 
that the consequences of local IL-31 inhibition can be studied.  
Besides its contribution to skin diseases recent evidence suggests a role of IL-31 and 
OSM in itch and neuroimmune communication (Cevikbas et al., 2014). By using gene 
delivery by adeno-associated virus-derived (AAV) vectors it is possible to target specific 
tissues. The AAV serotype 5 has been reported to mediate effective gene delivery to dor-
sal root ganglia (DRG) (Mason et al., 2010), and further improvements to vectors have 
been made for simultaneous expression of two genes of interests (Fagoe et al., 2014). 
Combined or single gene delivery to DRG of i.e. mOSM-RFP and mIL-31-RFP could 
5 Discussion 93 
further clarify the distinct contribution and role of both cytokines to itch and neuroim-
mune communication mediated by DRG signaling in pruritic skin tissues. 
Another role has been proposed for IL-31 in the regulation of intestinal barrier function 
contributing to the pathogenesis of IBD. Both IL-31R and OSMR are expressed on intes-
tinal epithelial cells (IEC). Additionally colonic lesions of IBD patients show increased 
IL-31 mRNA expression (Dambacher et al., 2007). Interestingly recent evidence hints at 
a similar role for OSM in IBD. OSM signaling through type II OSM receptor complex 
(OSMR/gp130) leads to increased IEC proliferation and wound healing. Further colonic 
biopsies of patients with active IBD (Beigel et al., 2014) show upregulated OSM protein 
expression. Again concurrent use of both mOSM-RFP and mIL-31-RFP could help to 
further dissect cytokine networks in IBD. 
5.2 Transgenic mice with inducible expression of mIL-6-RFP 
In this project, the previously described mIL-6-RFP-V5-his (Wiesinger et al., 2009) was 
optimized for the transfer to a tetracycline inducible system that is well suited for the 
generation of transgenic mice and allows controlled expression of the fusion protein in 
space and time. First the V5-his tag was replaced with a 3V5-3HA tag module (Figure 
12), allowing reliable ELISA based quantification from conditioned media and serum 
samples. The tag exchange did not influence biological activity in terms of IL-6 binding 
and inhibition of IL-6 induced STAT3 phosphorylation (Figure 13). The vector system 
of choice was the tetracycline controlled pTRE-Tight-BI vector system (Figure 14). 
Transient expression analysis in HEK293 cells revealed a strong dependence on the 
presence of the rtTA-M2. Basal expression, but low secretion levels, of mIL-6-RFP-3V5-
3HA could be observed even without the addition of doxycycline in cells co-transfected 
with the corresponding vectors encoding for rtTA-M2 and mIL-6-RFP-3V5-3HA. But 
treatment with doxycycline led to a strong induction of mIL-6-RFP expression and se-
cretion. Without the presence of the rtTA-M2 no mIL-6-RFP expression was detectable 
(Figure 15). The latter is an important aspect in the generation of mice with rtTA-M2-
/doxycycline-controlled mIL-6-RFP expression. Tissues and cells that don’t carry the 
5 Discussion 94 
rtTA-M2 transgene will not express any mIL-6-RFP. Therefore localized expression is 
governed by the activity of the promoter controlling rtTA-M2 expression. 
In the next step we were able to create two independent transgenic founder mice identi-
fied through PCR based genotyping from tail DNA (Figure 16), that were subsequently 
crossed with LAP:rtTA and Pod:rtTA mouse lines to target the liver and podocytes of 
the kidney for localized mIL-6-RFP expression (Figure 17). Additional pronuclear injec-
tions failed to generate transgene positive mice. As we are dealing with transgenic mice, 
each Tg(TET:mIL-6-RFP) founder mice has a random insertion site for the transgene 
accompanied with different transcriptional activity. In the analysis of Tg(TRE:mIL-6-
RFP, LAP:rtTA)1F1 mice we were able to detect some mIL-6-RFP and lacZ mRNA ex-
pression in mice (Figure 18 A+B), but we failed to detect any mIL-6-RFP protein by 
means of Western Blot of liver lysates and serum (Figure 18 C+D), or ELISA from se-
rum samples directed against the V5-HA tag module. We then co-transfected 
Tg(LAP:rtTA) mice with vectors encoding doxycycline-inducible and rtTA-dependent 
mIL-6-RFP/lacZ expression and constitutive expression of eGFP. X-Gal staining from 
liver sections revealed low and mosaicism-like lacZ expression (Figure 19 A), whereas 
immunofluorescence analysis showed eGFP expression in more than 50% of the liver 
tissue (Figure 19 B). In this scenario lacZ expression depends on rtTA-M2 expression 
and doxycycyline activation, whereas eGFP is expressed constitutively. This either 
speaks for either low to none rtTA-M2 levels in liver of Tg(LAP:rtTA). 
In Tg(TET:mIL-6-RFP.tg1/pod:rtTA)2F1 mice we could detect lacZ gene expression 
through X-Gal staining from kidney sections (Figure 20 A). This staining is in line with 
a report originally describing the podocyte specific expression of the lacZ gene 
(Shigehara et al., 2003). Unfortunately we also failed to detect any mIL-6-RFP protein by 
means of Western blot analysis from kidney lysates (Figure 20 B), or ELISA from serum 
samples directed against the V5-HA tag module (data not shown). 
For missing protein expression in transgenic mice various factors have to be considered: 
Effective transgene expression depends on the place of integration, and as mentioned 
before pronucleus injection of linearized DNA leads to random integration into the host 
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genome. Heterochromatin regions of the mouse genome are often affected by gene si-
lencing effects. Therefore the histone and DNA methylation status of the inserted 
transgene in different tissues would be worth to investigate. Also tissue-specific silenc-
ing of the CMV promoter has been reported. In the liver silencing of the CMV promot-
er might not be due to DNA methylation but instead through transcriptional repressors 
binding to elements on the promoter (Loser et al., 1998). A specific repressive factor 
may act upon the minimal CMV promoter. It may therefore be necessary to screen cell 
types with poor CMV activity with different minimal promoters to find their most ac-
tive enhancer elements. In our system another important factor that controls transgene 
expression is the tissue penetration of the administered doxycycline. Protein expression 
could further be negatively influenced by transcript regulation through cell-type specific 
microRNA expression patterns that target in the case of mIL-6-RFP either the gp130 or 
IL-6Rα portion. Taken together expression of mIL-6-RFP transgene could be silenced or 
negatively regulated due to yet unknown reasons or mechanisms on either genetic or 
transcriptional levels. Further clarification would be necessary. 
5.3 Optimization of mIL-6-RFP 
5.3.1 Design of mIL-6-RFP-Fc 
Although the first transgenic approach described previously did not result in any meas-
urable and detectable protein, we thought about further modifications to the design, 
expression system and type of transgene delivery of mIL-6-RFP-3V5-3HA. As a first 
measure we added the hinge region and crystallizable fragment (Fc) domain of an engi-
neered mIgG2a to mIL-6-RFP-3V5-3HA. The resulting fusion protein mIL-6-RFP-Fc-
3V5-3HA (mIL-6-RFP-Fc) is homodimeric, containing two entities mIL-6-RFP-3V5-
3HA (Figure 21). Responsible are cysteine residues within the Fc-fragment that enforce 
dimerization through disulfide bond formation thereby favoring the formation of an 
inhibitory complex consisting of a mIL-6-RFP-Fc dimer that binds two IL-6 molecules. 
This stoichiometry is analogous to the high-affinity hexameric receptor complex con-
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sisting of two molecules of each IL-6, sIL-6Rα and gp130 that has been verified by X-ray 
crystallography (Boulanger et al., 2003). Earlier work demonstrated that IL-6-RFP in-
deed forms complexes similar to the native IL-6 receptor complex (Metz et al., 2007). 
The homodimeric character of mIL-6-RFP-Fc increases its avidity towards IL-6, which 
is reflected in the tenfold increase of its inhibitory activity on IL-6-dependent cell prolif-
eration compared to the original mIL-6-RFP (Figure 27). Furthermore, the Fc-fragment 
of IgG interacts with the neonatal Fc receptor (FcRn) that mediates recycling of pinocy-
tosed protein, thus increasing the plasma half-life of the fusion protein (Rath et al., 
2013). This feature can be further modulated through mutations that affect the Fc-FcRn 
interaction (Vaccaro et al., 2005).  Finally, when mIL-6-RFP-Fc is produced as a recom-
binant protein the Fc fragment allows convenient purification through affinity chroma-
tography with immobilized Protein A or G. As its predecessor, mIL-6-RFP-Fc can be 
reliably quantified with an ELISA directed against the two triple tags (3V5-3HA) that 
follow the Fc-fragment. By simple cloning procedures, the Fc-3V5-3HA module can be 
easily transferred to other receptor fusion proteins so that different proteins can be 
quantified by the same assay and acquire additionally the Fc mediated properties.  
5.3.2 Codon Optimization 
In a second step we optimized the cDNA of mIL-6-RFP-Fc based on mammalian codon 
usage (Figure 22). Further sequences that could interfere with stability and translation of 
the transcribed mRNA were removed. Recently it was reported that optimization of co-
dons modulate the translational elongation rates. Significant alterations in tRNA con-
centrations between cells and tissues can alter the mRNA expression profile and dynam-
ically change mRNA stability (Presnyak et al., 2015). Also negative regulatory effects on 
mIL-6-RFP-Fc expression at the translational level mediated by cell-type specific miR-
NAs would be avoided by codon optimization.  
The optimized cDNA was subcloned into various vector systems suited for either in 
vitro protein expression, in a transient or stable manner, and finally a vector system well 
suited for the generation of either transgenic mice or gene delivery approaches to ana-
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lyze the efficacy of mIL-6-RFP-Fc in vivo. Comparative analysis following transient 
transfection of the optimized mIL-6-RFP-Fc cDNA vs. non-optimized cDNA revealed a 
2.5-fold or 1.6-fold increase in protein secretion from either human or murine liver de-
rived cells, respectively (Figure 23). HEK293 Flp-In/T-Rex were stably transfected with 
the optimized mIL-6-RFP-Fc cDNA and subjected to clonal selection (Figure 24). Con-
tinuous protein production yielded about 4 mg mIL-6-RFP-Fc per liter of conditioned 
medium (data not shown). The purity of recombinant mIL-6-RFP-Fc was high as there 
were no impurities and signs of degradations in the Coomassie stained gel (Figure 25). 
5.3.3 Biochemical characterization of mIL-6-RFP-Fc 
mIL-6-RFP-Fc inhibited IL-6-dependent STAT3-phosphorylation already at equimolar 
concentration in muHepa cells, whereas pretreatment with a 10-fold molar excess of 
mIL-6-RFP-Fc completely inhibited signal transduction by IL-6 (Figure 26). Further 
mIL-6-RFP-Fc inhibits IL-6-induced proliferation of Ba/F3-mgp130/mIL-6Rα cells. The 
forced dimerization through Fc-fusion leads to an improved inhibitory profile as evi-
dent by the 10-fold lower IC50 in comparison to the monomeric mIL-6-RFP (Figure 
27). This is in agreement with the higher avidity of mIL-6-RFP-Fc as proposed in our 
model and with the increase of the activity of the IL-6 trans-signaling inhibitor sgp130 
upon Fc fusion (Jostock et al., 2001). 
Complete blockade of all receptor binding sites of IL-6 by mIL-6-RFP-Fc could have a 
direct impact on its activity in a clinical setting. A direct comparison of  two TNF-α in-
hibitors, namely Etanercept, a TNFR-Fc fusion protein, and infliximab, an anti-TNF-α 
antibody, has shown that differences in binding stoichiometry and affinity might lead to 
different clinical outcomes (Scallon et al., 2002). Etanercept can interact by design just 
with two binding sites within the TNF-α trimer in a 1:1 stoichiometry even in molar 
excess, leaving one available binding site, whereas infliximab binds the TNF-α trimer in 
a 3:1 stoichiometry, fully blocking all binding sites. Both biologics ameliorate disease 
characteristics in RA patients, whereas only infliximab seems to be effective in the 
treatment of Crohn’s disease patients. 
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5.3.4 Pharmacological properties of recombinant mIL-6-RFP-Fc 
To assess the usefulness as a potential therapeutic the pharmacokinetics of mIL-6-RFP-
Fc were analyzed. Intraperitoneally injected mIL-6-RFP-Fc showed the highest serum-
bioavailability compared to intravenous or subcutaneous administration (Figure 28 A). 
Two hours following intraperitoneal delivery mIL-6-RFP-Fc serum bioavailability was 
about 40%. At the highest amount (40 μg) applied in one single administration, mIL-6-
RFP-Fc could be detected in serum for up to 48 h (Figure 28 B). The dominant half-life 
of mIL-6-RFP-Fc was about 3.5 h and is identical with the initial clearing determined for 
an IL-2-Fc fusion protein harboring the same Fc-fragment of mIgG2a (Zheng et al., 
1999). 
5.3.5 mIL-6-RFP-Fc inhibits IL-6 signaling in vivo 
The pretreatment of mice through systemic administration of recombinant mIL-6-RFP-
Fc by intraperitoneal injection decreased IL-6-induced STAT3 and ERK phosphoryla-
tion in the liver and the kidney of IL-6 treated mice (Figure 30). Thus circulating mIL-6-
RFP-Fc penetrates into the liver and kidney, is biologically active and inhibits IL-6 de-
pendent signal transduction in vivo. 
5.3.6 Gene delivery of monogenic RFPs 
As production and purification of recombinant protein is time-consuming, tedious and 
costly, we explored the potential use of monogenic RFPs for gene therapy. Targeted 
gene transfer allows cytokine inhibition at sites of inflammation by enabling local, sus-
tained and potentially regulated expression of receptor fusion proteins. Endogenously 
produced proteins as a result of gene transfer are nascent molecules that have under-
gone post-translational modification with glycosylation patterns that are entirely host-
like. This feature is expected to dramatically reduce immunogenicity which often is a 
result of aberrant non-host-like glycosylation by i.e. recombinant protein production in 
different expression systems  (Baker et al., 2010). 
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In our study, we used the experimental method of hydrodynamic transfection for gene 
delivery of mIL-6-RFP-Fc (Liu et al., 1999). For gene delivery we chose a vector system 
under the transcriptional control of the PEPCK promoter, previously described for the 
generation of transgenic mice expressing either sIL-6Rα (Peters et al., 1996) or sgp130-
Fc (Rabe et al., 2008). The PEPCK promoter is mainly active in the liver and kidney 
(Beale et al., 1992). A β-globin intron, located between promoter and open-reading-
frame (ORF) should lead to more efficient translation of the intron-containing tran-
script or spliced mRNA (Lee et al., 2009). Previous experiments of Wiesinger et al. ini-
tially tested intramuscular electrotransfer of the previously reported mIL-6-RFP-V5-his 
to rats. 72 hours after electroporation of rat serum levels were in the range of 0.4 to 0.7 
ng/ml (Wiesinger, 2008). Following hydrodynamics-based transfection of mIL-6-RFP-
Fc into mice, obtained serum levels of the fusion protein were stable for at least 48 hours 
in the range of 0.5 to 4 μg/ml (Figure 32), which marks a 1.000 to 10.000 fold increase 
when compared to mIL-6-RFP-V5-his serum levels after electrotransfer into rats. Host-
expressed mIL-6-RFP-Fc was detectable for up to 7 days (Figure 32). 
Resolution of the Acute Phase Response 
The acute phase response (APR) is part of the innate immune response and is triggered 
by pro-inflammatory cytokines as a result of local or systemic disturbances (Ruminy et 
al., 2001). Acute phase proteins (APP) are produced predominantly by hepatocytes and 
are induced by the pro-inflammatory cytokines IL-1, TNF-α and IL-6 under acute in-
flammatory conditions. In mice, the predominant APP belong to the SAA family. IL-6 is 
regarded as the major inducer of acute phase protein synthesis in the liver (Ritchie and 
Fuller, 1983, Gabay and Kushner, 1999). 
The experimental procedure of hydrodynamics-based transfection leads to liver stress as 
evident by the transient increase of alanine aminotransferase (ALT) levels, a marker for 
hepatocyte damage, post injection independent of the presence of plasmid DNA (Liu et 
al., 1999). Following hydrodynamic delivery we could observe upregulated mRNA ex-
pression of the two acute phase proteins SAA1 and A2M 24 hours post transfection 
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(Figure 31D) and also in the I/R model 48 hours after transfection (Figure 34). Expres-
sion for both SAA1 and A2M mRNAs was markedly reduced in mIL-6-RFP-Fc trans-
fected mice compared to control animals (Figure 31D and Figure 34). This result 
demonstrates that host-produced mIL-6-RFP-Fc is biologically active and mIL-6-RFP-
Fc serum levels are sufficient to resolve IL-6-dependent acute phase response as a con-
sequence of local disturbances caused by the hydrodynamic events in the liver. Resolu-
tion of the acute phase protein synthesis correlated with increased mIL-6-RFP-Fc levels 
(Figure 34, right panels). 
5.3.7 IL-6 in ischemia reperfusion injury of the kidney 
Finally we used the host-expressed inhibitor to assess its bioactivity and therapeutic po-
tential in an experimental model of acute kidney injury (AKI). We employed the model 
of bilateral ischemia/reperfusion injury of the kidney (Figure 33). Ischemia/reperfusion 
shows a complex pathophysiology. It affects many regulatory systems at the cellular lev-
el, i.e. on energy metabolism, loss of tubular cell polarity and development of acute tub-
ular necrosis (ATN) (Devarajan, 2005). Release of chemokines and cytokines in renal 
tissues leads to the activation of distinct inflammatory events (Salvadori et al., 2015).  
Although the role of IL-6 in renal ischemic injury is controversial, studies in mice high-
light a contribution of IL-6 to the development of AKI, and that inhibition of IL-6 ame-
liorates kidney damage (Kielar et al., 2005, Patel et al., 2005). Renal injury by ische-
mia/reperfusion has been mainly attributed to increased IL-6 production of macrophag-
es in the context of injured proximal tubular cells (Kielar et al., 2005). IL-6-/- mice or 
mice that were treated with a neutralizing anti-IL-6 antibody show a reduction of the 
increased plasma urea and serum creatinine levels caused by I/R (Patel et al., 2005).  
We investigated the potential of mIL-6-RFP-Fc to ameliorate acute kidney injury caused 
by I/R. Indeed mice that underwent hydrodynamic transfection of mIL-6-RFP-Fc prior 
to induction of ischemic renal injury showed a significant reduction of serum creatinine 
levels compared to control mice (Figure 35A), reduced tubular damage as assessed by 
reduced NGAL mRNA expression (Figure 35B) and tubular injury scoring (Figure 35C). 
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A large variance within the IL-6-/- groups in the I/R model was also observed in another 
study (at least twofold of the wildtype control groups) (Kielar et al., 2005). To better 
understand this phenomenon a careful correlation analysis of the 20 h serum mIL-6-
RFP-Fc levels and the associated renal outcomes was undertaken. While the animal with 
the highest serum level of 4.5 μg/ml exhibited the lowest serum creatinine level (0.21 
mg/dl) and the lowest average NGAL expression level (right kidney: 40-fold, left kidney 
156-fold of normal) no clear correlation between these outcome markers and the mIL-
6-RFP-Fc level was found in the other animals (data not shown). On the other hand, a 
clear dose-response effect was observed in the inhibition of the hepatic acute phase re-
sponse (Figure 34, right panels). 
Intriguingly, in the hepatic stress response at 24 h following hydrodynamics based 
transfection (Figure 31D) acute phase transcriptional suppression by mIL-6-RFP-Fc is 
significant but incomplete while in the I/R model it is total with some animals ranging 
below the level of healthy controls (Figure 34, right panels). Indeed, as discussed above, 
24 h post hydrodynamics stress non-IL-6 driven SAA1 transcription by IL-1 or TNF 
might be the case, while for the I/R model it has been elegantly established that IL-6 is 
mainly derived from the kidney contributing to high systemic levels (Kielar et al., 2005). 
Renal IL-1 and TNF release is a feature of I/R but not in the setting of IL-6-/- or antago-
nism (Patel et al., 2005). Collectively, this could explain the discrepancy between acute 
phase transcriptional suppression in hepatic stress and I/R. 
5.4 Outlook 
5.4.1 Design of hIL-6-RFP-Fc 
In this study we found a rather short circulating t1/2 for mIL-6-RFP fused to Fc from 
mIgG2A. An analogous hIL-6-RFP should be fused to Fc of human IgG1 that harbors 
the M252Y/S254T/T256E (YTE) mutations to improve serum half-life. The YTE triple 
mutation has been shown to increase affinity of IgG1-Fc to human FcRn tenfold, result-
ing in a 4-fold increase in serum-half-life in cynomolgus monkeys (Dall'Acqua et al., 
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2006). Other hIgG1-Fc-fusion proteins exert variable half-life’s, ranging from 4 to 23 d 
(Suzuki et al., 2010). Additionally species identity of the human Fc part should reduce 
immunogenicity. 
For other analogous hIgG1-Fc-fusion proteins that are to be used in a murine model of 
human disease, there is also to keep in mind that human IgG1 has a stronger affinity to 
murine FcRn than to human FcRn (Neuber et al., 2014). Therefore for pharmacological 
studies, mouse strains that express human rather than murine FcRn should be used 
(Roopenian et al., 2010, Tam et al., 2013). 
5.4.2 Design of an RFP targeting IL-11 
The approach of gene delivery of monogenic cytokine inhibitors is not confined to IL-6 
and can be exploited to target other cytokines that signal through heteromeric cytokine 
receptors. For instance, through replacement of the IL-6Rα moiety by the IL-11Rα, a 
mIL-11-RFP-Fc can be generated that is expected to potently block IL-11, another cyto-
kine of the IL-6 family (Schwache and Müller-Newen, 2012). IL-11 has been recently 
identified as a dominant cytokine during gastrointestinal tumorigenesis (Putoczki et al., 
2013). 
5.4.3 Gene therapy 
The main advantages of gene therapy over the use of recombinant proteins are mainte-
nance of sustained and therapeutically relevant concentration of the protein eliminating 
the limitations of recombinant protein production and delivery. Additionally gene ther-
apy allows for targeted and local gene expression rather than systemic availability of the 
therapeutic protein. 
Methods for non-viral gene delivery of monogenic RFPs 
Hydrodynamic Gene Delivery The experimental method of hydrodynamic transfec-
tion allowed us to effectively characterize the biological action of mIL-6-RFP-Fc in vivo 
but obviously this mode of gene delivery will not be suited for the treatment of humans 
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but is an option to consider in preclinical animal models (Katsimpoulas et al., 2012). 
Hydrodynamics-based transfection of naked plasmid DNA is of transient nature. A re-
cent study reported the use of a cationic polymer carrier solution, which improved 
transfection efficiency of murine liver hepatocytes 2.5-fold in the liver of transfected 
animals compared to the conventional use of naked plasmid DNA (Nakamura et al., 
2013). 
Minicircular DNA (Minicircle) Another possibility to non-virally transfer monogenic 
RFPs in vivo uses minicircular DNA. Minicircular DNA (Minicircle) lacks bacterial se-
quences and has been shown to express superior amounts of serum human factor IX 
and α1-antitrypsin compared to standard plasmid DNAs transfected into mouse liver 
(Chen et al., 2003). Meanwhile bacterial systems have been developed that facilitate the 
production of purified minicircles in a time frame and quantity similar to those of rou-
tine plasmid DNA preparation (Kay et al., 2010). Recently, the well-established anti-IL-
6-Rα antibody tocilizumab has been demonstrated to be effectively deliverable through 
hydrodynamic gene delivery by minicircular DNA (Yi et al., 2014). However this anti-
body required two separate minicircles, given the nature of antibody assembly from two 
chains. This is simplified by the approach presented herein. 
DNA-functionalized gold-nanoparticles (GNP) For the therapy of inflammatory 
bowel diseases, a proof-of-concept study described the encapsulation of DNA-
functionalized GNPs into primary isolated intestinal stem cells that could act as a Trojan 
horse for gene regulation therapies in inflammatory bowel disease (IBD). (Peng et al., 
2015).  
Methods for safe viral gene delivery of monogenic RFPs 
For future therapeutic applications in patients, an analogous hIL-6-RFP-Fc designed for 
delivery through safe virus-based transfection methods such as integrating lentiviral 
vectors or non-integrating adeno-associated virus-derived vectors will be required.  
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Adeno-associated Virus (AAV) Adeno-associated viruses (AAV) are non-pathogenic 
in humans, and most importantly replication-defective in the absence of a helper virus 
(Mingozzi and High, 2011). Therefore AAVs are considered safe and have been success-
fully used in gene therapeutic studies. Wildtype (wt) AAV contains a single-stranded 
DNA genome within an icosahedric capsid of 25 nm diameter. The different AAV sero-
types have tropism for a number of post-mitotic, long-lived cell types. AAV2, the best 
characterized of 12 different AAV serotypes, has a genome size of 4680 nucleotides with 
two open reading frames (ORFs) encoding for the capsid proteins (cap) and replication 
proteins (rep). The ORFs are further flanked by the inverted terminal repeats (ITR). In 
recombinant AAV (rAAV) the cap and rep ORFs are replaced with a transgene of inter-
est. The transgene, composed of the therapeutic gene of interest, introns, polyadenyla-
tion signals and controlling promoter, should not exceed 5 kb and is integrated between 
both ITRs. For rAAV production rep/cap are delivered in trans with helper plasmids in 
HEK293 cells (Grimm et al., 2003) or in the insect cell line Sf9 (Mietzsch et al., 2014).  
After transduction and transformation of the recombinant genome into stable episomal 
forms within the cell, long-term expression can be achieved even though integration 
into the genome has not occurred. The fusion protein p75-TNFR:Fc has been success-
fully delivered by AAV in animal models of rheumatoid arthritis as an alternative ap-
proach to TNF-α blockade with recombinant protein and showed long-term disease 
suppression (Sandalon et al., 2007). Similarly, rAAVs can be designed for targeted gene 
delivery and controlled expression of murine or human IL-6-RFP-Fc by different choic-
es of organ- or tissue-specific promoters so that the consequences of local IL-6 inhibi-
tion can be studied.  
5.4.4 Decyphering cytokine networks of IL-6 type cytokines 
The IL-6 family of cytokines shares gp130 as a common β-chain receptor, which already 
hints at a system with great plasticity (Garbers et al., 2012). RFP are great tools to clarify 
the individual contributions of IL-6-type cytokines. Both for rheumatoid arthritis 
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(Wong et al., 2003) and inflammatory bowel disease (Neurath, 2014) the complex net-
works of cytokines including the IL-6 family of cytokines have been recognized.  
Cytokine networks in IBD 
OSM signal transduction in humans and rats can occur through two different types of 
receptors. OSM either signals through type I receptor complex consisting of 
LIFR/gp130, or the type II receptor complex consisting of OSMR/gp130, whereas in 
mice OSM signaling only occurs through the type II receptor complex (Drechsler et al., 
2012). An important structural aspect in OSM that governs receptor affinity in humans 
is the presence of a BC-loop. Besides OSM the novel cytokine IL-31 has been shown to 
signal through OSMR. It has been described that IL-31R-/- mice show increased respon-
siveness to OSM (Bilsborough et al., 2010). So far it has not been shown, if either IL-31 
dampens OSM-dependent signaling through OSMR by competition for receptor bind-
ing, or the other way around. In MEF mIL-31R cells OSM leads to more potent STAT3 
activation than IL-31. It would be interesting to further dissect if shifts of target gene 
expression profiles can occur in vivo by interference through receptor fusion proteins 
targeting either IL-31 or OSM. A similar type of regulation has already been described 
for the LIF/OSM system. Cytokine signaling at the receptor level is governed by the in-
dividual affinity of cytokine-receptor interactions, soluble and membrane-bound recep-
tor expression levels, and finally local cytokine levels. 
5.4.5 Potential therapeutic applications for IL-6-RFPs in anti-IL-6 therapy 
Lipid apheresis 
Similar to the observed reduction of lipoprotein(a) serum levels in RA patients by anti-
IL-6R treatment (Schultz et al., 2010), a recent study highlights the ability of anti-IL-6 
treatment to lower elevated serum lipoprotein(a) concentrations leading to a reduced  
risk in developing cardiovascular diseases which presents a convenient alternative to 
costly and invasive lipid apheresis (Mueller et al., 2015).  
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Rheumatoid arthritis 
Preclinical studies should explore modes of local inhibition of IL-6 by gene therapy as 
an alternative to systemic administration of antibodies targeting IL-6 in models of 
rheumatoid arthritis. Hybrid promoter systems consisting of the human IL-1 enhancer 
sequence in front of the human IL- 6 promoter allows autoregulation of transgene ex-
pression during arthritis (van de Loo et al., 2004) and could be used to express IL-6-
RFPs in synovial joints. 
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6 Summary 
Cytokines are small soluble proteins with regulatory functions in many biological pro-
cesses including immune responses. Dysregulated cytokine signaling is often responsi-
ble for the development and maintenance of acute and chronic inflammation. Current 
anti-cytokine therapies have substantially improved the treatment of inflammatory dis-
eases. Cytokine-targeting drugs are usually biologics such as neutralizing antibodies or 
soluble receptors. To target cytokines that signal through heteromeric receptor com-
plexes we developed a strategy that involves the inline fusion of the ligand binding do-
mains of the corresponding receptor subunits. These receptor fusion proteins (RFPs) 
are highly potent and specific, monogenic by design, and therefore well suited for gene 
transfer approaches. 
The first part of this project deals with the development of a novel RFP targeting mu-
rine interleukin-31 (IL-31). IL-31, mostly involved in skin diseases, signals through het-
erodimeric receptor complexes comprised of the interleukin-31 receptor (IL-31R) and 
the oncostatin M receptor (OSMR) subunits.  
 mIL-31-RFP was created by inline fusion of domains D1-D4 of murine OSMR 
and domains D1-D2 of murine IL-31R connected by a flexible linker and 
equipped with a 3V5-3HA-tag module to facilitate protein quantification and 
detection. 
 Full-length mIL-31R cDNA was rebuilt by PCR fusion of missing exons from 
genomic DNA to Isoform 4. Subsequently MEF cells were stably transfected with 
mIL-31R to establish a cell-based system for the analysis of murine IL-31 and 
OSM signaling. 
 mIL-31-RFP effectively and specifically inhibited IL-31-dependent signal-
transduction and did not interfere with the activity of mOSM. 
 HEK293 Flp-In/T-Rex cells were stably transfected with mIL-31-RFP cDNA, 
subjected to clonal selection for the production of recombinant mIL-31-RFP. 
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In the second part of this project, we investigated, as a proof-of-principle for other 
monogenic RFPs, the potential of the previously described mIL-6-RFP to inhibit inter-
leukin-6 (IL-6) in vivo. Dysregulated persistent IL-6 production plays a pathological role 
in various autoimmune and chronic inflammatory diseases. Therefore, transgenic mice, 
that express mIL-6-RFP in an inducible and tissue-specific manner, were generated and 
characterized.  
 First the V5-his-tag of the previously described mIL-6-RFP was exchanged with 
a 3V5-3HA-tag module to facilitate protein detection and quantification from 
serum of mice. The tag exchange did not influence its biological activity of mIL-
6-RFP. 
 mIL-6-RFP-3V5-3HA was efficiently expressed and secreted from HepG2 cells 
transiently transfected with the individual components of the expression system 
to be used in transgenic mice. 
 Two independent Tg(TRE:mIL-6-RFP-3V5-3HA) mouse lines could be generat-
ed following pronucleus injection, and were subjected to further breeding. Gen-
erated mouse lines were crossed with Tg(LAP:rtTA) and Tg(Pod:rtTA) to gener-
ate double transgenic mice. 
 Unfortunately, double transgenic mice did not express any measurable protein 
levels of mIL-6-RFP-3V5-3HA in either serum or in corresponding tissues.  
In a parallel approach, we re-engineered mIL-6-RFP by fusion to the Fc of mIgG2a 
(mIL-6-RFP-Fc) for enhanced inhibitory activity and improved protein expression by 
codon optimization.  
 Codon optimization led to increased mIL-6-RFP-Fc protein expression in 
HepG2 (2.5 fold) and muHepa cells (1.6 fold) compared to non-optimized 
cDNA following transient transfection of vectors encoding for mIL-6-RFP-Fc. 
 HEK293 Flp-In/T-Rex cells were stably transfected with optimized mIL-6-RFP-
Fc cDNA, and subjected to clonal selection for the production of recombinant 
mIL-6-RFP-Fc.  
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 mIL-6-RFP-Fc inhibited IL-6-dependent STAT3 phosphorylation in muHepa 
cells in vitro already at equimolar concentrations.  
 mIL-6-RFP-Fc inhibited IL-6-dependent Ba/F3-mgp130/mIL-6Rα cell prolifera-
tion with a tenfold increased inhibitory activity when compared to mIL-6-RFP-
V5-his. 
 Upon application in mice, recombinant mIL-6-RFP-Fc inhibited IL-6-induced 
activation of the transcription factor STAT3 and ERK1/2 kinases in liver and 
kidney. 
 Gene transfer through hydrodynamic plasmid delivery in mice resulted in hepat-
ic production and secretion of mIL-6-RFP-Fc into the blood in considerable 
amounts, blocked hepatic acute-phase protein synthesis and improved kidney 
function in an ischemia and reperfusion injury model.  
Our study establishes receptor fusion proteins as promising agents in anti-cytokine 
therapies through gene therapeutic approaches for future targeted and cost-effective 
treatments. The strategy described here is applicable for many cytokines involved in 
inflammatory and other diseases. 
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